<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0168365913001521</prism:url><dc:identifier>doi:10.1016/j.jconrel.2013.03.009</dc:identifier><eid>1-s2.0-S0168365913001521</eid><prism:doi>10.1016/j.jconrel.2013.03.009</prism:doi><pii>S0168-3659(13)00152-1</pii><dc:title>Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord </dc:title><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01683659</prism:issn><prism:volume>168</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>209</prism:startingPage><prism:endingPage>224</prism:endingPage><prism:pageRange>209-224</prism:pageRange><prism:number>2</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2013-06-10</prism:coverDate><prism:coverDisplayDate>10 June 2013</prism:coverDisplayDate><prism:copyright>Copyright © 2013 Elsevier B.V.</prism:copyright><prism:publisher>Elsevier B.V.</prism:publisher><dc:creator>Dengler, Ellen C.</dc:creator><dc:creator>Liu, Juewen</dc:creator><dc:creator>Kerwin, Audra</dc:creator><dc:creator>Torres, Sergio</dc:creator><dc:creator>Olcott, Clara M.</dc:creator><dc:creator>Bowman, Brandi N.</dc:creator><dc:creator>Armijo, Leisha</dc:creator><dc:creator>Gentry, Katherine</dc:creator><dc:creator>Wilkerson, Jenny</dc:creator><dc:creator>Wallace, James</dc:creator><dc:creator>Jiang, Xingmao</dc:creator><dc:creator>Carnes, Eric C.</dc:creator><dc:creator>Brinker, C. Jeffrey</dc:creator><dc:creator>Milligan, Erin D.</dc:creator><dc:description>AbstractAmorphous mesoporous silica nanoparticles (‘protocells’) that support surface lipid bilayers recently characterized in vitro as carrier constructs for small drug and DNA delivery are reported here as highly biocompatible both in vitro and in vivo, involving the brain and spinal cord following spinal delivery into the lumbosacral subarachnoid space (intrathecal; i.t.). Specifically, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)–cholesterol (DOTAP:Chol) liposome-formulated protocells revealed stable in vitro cargo release kinetics and cellular interleukin-10 (IL-10) transgene transfection. Recent approaches using synthetic non-viral vector platforms to deliver the pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space have yielded promising results in animal models of peripheral neuropathy, a condition involving aberrant neuronal communication within sensory pathways in the nervous system.Non-viral drug and gene delivery protocell platforms offer potential flexibility because cargo release-rates can be pH-dependent. We report here that i.t. delivery of protocells, with modified chemistry supporting a surface coating of DOTAP:Chol liposomes and containing the IL-10 transgene, results in functional suppression of pain-related behavior in rats for extended periods. This study is the first demonstration that protocell vectors offer amenable and enduring in vivo biological characteristics that can be applied to spinal gene delivery.</dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType>Author</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by-nc-nd/3.0/</openaccessUserLicense><dcterms:subject>Interleukin-10 cytokine</dcterms:subject><dcterms:subject>Gene delivery</dcterms:subject><dcterms:subject>Biocompatibility</dcterms:subject><dcterms:subject>Neuropathic pain</dcterms:subject><dcterms:subject>Cell and tissue viability</dcterms:subject><dcterms:subject>Non-viral vector</dcterms:subject><link rel="self" href="http://api.elsevier.com/content/article/pii/S0168365913001521"/><link rel="scidir" href="http://www.sciencedirect.com/science/article/pii/S0168365913001521"/></coredata><objects><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3574" height="2523" size="2449554">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1612" height="3127" size="534449">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3127" height="2225" size="664185">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2761" height="1163" size="284664">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2341" height="3514" size="1457136">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3031" height="3478" size="932626">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="999" size="360448">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3054" height="3026" size="990595">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3605" height="2000" size="757454">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="781" size="336442">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="807" height="570" size="177160">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="364" height="706" size="74505">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="706" height="502" size="65066">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="623" height="262" size="29161">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="529" height="794" size="118568">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="685" height="786" size="114599">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="225" size="37787">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="690" height="684" size="96320">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="814" height="452" size="86785">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="176" size="42805">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="155" size="11381">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="84" height="163" size="3210">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="7863">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="2803">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="109" height="164" size="8504">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="143" height="164" size="4779">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="6131">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="165" height="163" size="6986">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="7513">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="77" size="6845">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913001521-fx1.sml?httpAccept=%2A%2F%2A</object></objects><scopus-id>84877066455</scopus-id><scopus-eid>2-s2.0-84877066455</scopus-eid><pubmed-id>23517784</pubmed-id><link rel="abstract" href="http://api.elsevier.com/content/abstract/scopus_id/84877066455"/><originalText><xocs:doc xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://be-prod3a/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271103</xocs:cid><xocs:ssids><xocs:ssid type="alllist">291210</xocs:ssid><xocs:ssid type="subj">291681</xocs:ssid><xocs:ssid type="subj">291789</xocs:ssid><xocs:ssid type="content">31</xocs:ssid><xocs:ssid type="oa">90</xocs:ssid></xocs:ssids><xocs:srctitle>Journal of Controlled Release</xocs:srctitle><xocs:normalized-srctitle>JOURNALCONTROLLEDRELEASE</xocs:normalized-srctitle><xocs:orig-load-date yyyymmdd="20130318">2013-03-18</xocs:orig-load-date><xocs:available-online-date yyyymmdd="20130318">2013-03-18</xocs:available-online-date><xocs:ew-transaction-id>2014-09-08T16:38:32</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0168365913001521</xocs:eid><xocs:pii-formatted>S0168-3659(13)00152-1</xocs:pii-formatted><xocs:pii-unformatted>S0168365913001521</xocs:pii-unformatted><xocs:doi>10.1016/j.jconrel.2013.03.009</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.5</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0168365913X00082</xocs:hub-eid><xocs:timestamp yyyymmdd="20150514">2015-05-14T05:17:02.743021-04:00</xocs:timestamp><xocs:dco>0</xocs:dco><xocs:tomb>0</xocs:tomb><xocs:date-search-begin>20130610</xocs:date-search-begin><xocs:year-nav>2013</xocs:year-nav><xocs:indexeddate epoch="1363564800">2013-03-18T00:00:00Z</xocs:indexeddate><xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor primabst ref specialabst</xocs:articleinfo><xocs:issns><xocs:issn-primary-formatted>0168-3659</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>01683659</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NIH</xocs:funding-body-id><xocs:crossmark is-crossmark="1">true</xocs:crossmark><xocs:vol-first>168</xocs:vol-first><xocs:volume-list><xocs:volume>168</xocs:volume></xocs:volume-list><xocs:iss-first>2</xocs:iss-first><xocs:issue-list><xocs:issue>2</xocs:issue></xocs:issue-list><xocs:vol-iss-suppl-text>Volume 168, Issue 2</xocs:vol-iss-suppl-text><xocs:sort-order>9</xocs:sort-order><xocs:first-fp>209</xocs:first-fp><xocs:last-lp>224</xocs:last-lp><xocs:pages><xocs:first-page>209</xocs:first-page><xocs:last-page>224</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20130610</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>10 June 2013</xocs:cover-date-text><xocs:cover-date-start>2013-06-10</xocs:cover-date-start><xocs:cover-date-year>2013</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Gene Delivery</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 Elsevier B.V.</xocs:copyright-line><xocs:normalized-article-title>MESOPOROUSSILICASUPPORTEDLIPIDBILAYERSPROTOCELLSFORDNACARGODELIVERYSPINALCORD</xocs:normalized-article-title><xocs:normalized-first-auth-surname>DENGLER</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>E</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Animals</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>Behavioral assessment for sensory changes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title>Chronic constriction injury (CCI)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title>Intrathecal (i.t.) injections</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of plasmid DNA</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of mesoporous cationic silica “core” protocells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of liposome-supported bilayers (protocells)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of DNA (either 18-bp or pDNA) loaded “protocells”</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.9</xocs:item-toc-label><xocs:item-toc-section-title>Characterization of mesoporous silica particles</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.10</xocs:item-toc-label><xocs:item-toc-section-title>Characterization of cargo release-rate from protocells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.11</xocs:item-toc-label><xocs:item-toc-section-title>Examination of tissue samples by fluorescence microscopy</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.12</xocs:item-toc-label><xocs:item-toc-section-title>Quantitative spectral imaging</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.13</xocs:item-toc-label><xocs:item-toc-section-title>Immunohistochemistry</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.14</xocs:item-toc-label><xocs:item-toc-section-title>Confocal imaging</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.15</xocs:item-toc-label><xocs:item-toc-section-title>Cellular transfection</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.16</xocs:item-toc-label><xocs:item-toc-section-title>Cell viability assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.17</xocs:item-toc-label><xocs:item-toc-section-title>Mouse macrophage (Raw 264.7) cells for nitric oxide assay</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.17.1</xocs:item-toc-label><xocs:item-toc-section-title>Measurement of nitric oxide production</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.18</xocs:item-toc-label><xocs:item-toc-section-title>Data analysis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vitro</ce:italic> cellular viability is substantial</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>Spinal delivery of protocells is well tolerated in an animal model</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title>Intrathecal (i.t.) DNA delivered by DOTAP:Chol or DOPC protocells remains closely associated with meninges</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.4</xocs:item-toc-label><xocs:item-toc-section-title>In vivo biodistribution of protocells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.5</xocs:item-toc-label><xocs:item-toc-section-title>Protocell IL-10 gene delivery leads to robust transgene expression</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.6</xocs:item-toc-label><xocs:item-toc-section-title>Protocells are functionally effective as gene delivery platforms</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4</xocs:item-toc-label><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>5</xocs:item-toc-label><xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>EDELSTEIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>833</xocs:ref-first-fp><xocs:ref-last-lp>842</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>KAISER</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>29</xocs:ref-first-fp><xocs:ref-last-lp>30</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>PEREZMARTINEZ</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1843</xocs:ref-first-fp><xocs:ref-last-lp>1858</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>MORILLE</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>3477</xocs:ref-first-fp><xocs:ref-last-lp>3496</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>TREWYN</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>3236</xocs:ref-first-fp><xocs:ref-last-lp>3245</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>ROGERS</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>183</xocs:ref-first-fp><xocs:ref-last-lp>189</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>18</xocs:ref-first-fp><xocs:ref-last-lp>25</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>HUDSON</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>4045</xocs:ref-first-fp><xocs:ref-last-lp>4055</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>ASHLEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>389</xocs:ref-first-fp><xocs:ref-last-lp>397</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>TARN</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>SLOWING</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>1278</xocs:ref-first-fp><xocs:ref-last-lp>1288</xocs:ref-last-lp></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>SLOANE</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1</xocs:ref-first-fp><xocs:ref-last-lp>13</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>SODERQUIST</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>841</xocs:ref-first-fp><xocs:ref-last-lp>854</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>2136</xocs:ref-first-fp><xocs:ref-last-lp>2148</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>BEUTLER</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>431</xocs:ref-first-fp><xocs:ref-last-lp>439</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>293</xocs:ref-first-fp><xocs:ref-last-lp>308</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>7567</xocs:ref-first-fp><xocs:ref-last-lp>7569</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1354</xocs:ref-first-fp><xocs:ref-last-lp>1355</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>CHAPLAN</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>55</xocs:ref-first-fp><xocs:ref-last-lp>63</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>105</xocs:ref-first-fp><xocs:ref-last-lp>116</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>2808</xocs:ref-first-fp><xocs:ref-last-lp>2819</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>BENNETT</xocs:ref-normalized-surname><xocs:ref-pub-year>1988</xocs:ref-pub-year><xocs:ref-first-fp>87</xocs:ref-first-fp><xocs:ref-last-lp>107</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>294</xocs:ref-first-fp><xocs:ref-last-lp>308</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>LANGER</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>5</xocs:ref-first-fp><xocs:ref-last-lp>10</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>CROOK</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>137</xocs:ref-first-fp><xocs:ref-last-lp>143</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>BARRETT</xocs:ref-normalized-surname><xocs:ref-pub-year>1951</xocs:ref-pub-year><xocs:ref-first-fp>373</xocs:ref-first-fp><xocs:ref-last-lp>380</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>4512</xocs:ref-first-fp><xocs:ref-last-lp>4513</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>BRUNAUER</xocs:ref-normalized-surname><xocs:ref-pub-year>1938</xocs:ref-pub-year><xocs:ref-first-fp>309</xocs:ref-first-fp><xocs:ref-last-lp>319</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>WILKERSON</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>155</xocs:ref-first-fp><xocs:ref-last-lp>177</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>HARVEY</xocs:ref-normalized-surname><xocs:ref-pub-year>1986</xocs:ref-pub-year><xocs:ref-first-fp>623</xocs:ref-first-fp><xocs:ref-last-lp>632</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>KHAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>393</xocs:ref-first-fp><xocs:ref-last-lp>404</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>671</xocs:ref-first-fp><xocs:ref-last-lp>679</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>QURESHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>177</xocs:ref-first-fp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>ZHA</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>2415</xocs:ref-first-fp><xocs:ref-last-lp>2418</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>KAWASAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>5189</xocs:ref-first-fp><xocs:ref-last-lp>5194</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>SAMAD</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>471</xocs:ref-first-fp><xocs:ref-last-lp>475</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>SAMAD</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>PROCSOCNEUROSCI</xocs:ref-normalized-srctitle><xocs:ref-normalized-article-title>CENTRALNEUROIMMUNEINTERACTIONSAFTERPERIPHERALINFLAMMATIONINTERLEUKIN1POTENTIATESSYNAPTICTRANSMISSIONINSPINALCORD</xocs:ref-normalized-article-title></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>SMITH</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>68</xocs:ref-first-fp><xocs:ref-last-lp>78</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>WATKINS</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>981</xocs:ref-first-fp><xocs:ref-last-lp>1011</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1796</xocs:ref-first-fp><xocs:ref-last-lp>1804</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>3568</xocs:ref-first-fp><xocs:ref-last-lp>3576</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>BIMBO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1068</xocs:ref-first-fp><xocs:ref-last-lp>1086</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>DAVIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>3864</xocs:ref-first-fp><xocs:ref-last-lp>3872</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>SACKMANN</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>43</xocs:ref-first-fp><xocs:ref-last-lp>48</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>60</xocs:ref-first-fp><xocs:ref-last-lp>62</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>TROUTIER</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1</xocs:ref-first-fp><xocs:ref-last-lp>21</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>2446</xocs:ref-first-fp><xocs:ref-last-lp>2451</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>SON</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>792639</xocs:ref-first-fp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0245"><xocs:ref-normalized-surname>MURPHY</xocs:ref-normalized-surname><xocs:ref-pub-year>1996</xocs:ref-pub-year><xocs:ref-first-fp>90</xocs:ref-first-fp><xocs:ref-last-lp>99</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>314</xocs:ref-first-fp><xocs:ref-last-lp>320</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>GINN</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>65</xocs:ref-first-fp><xocs:ref-last-lp>77</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0260"><xocs:ref-normalized-surname>GOSS</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>487</xocs:ref-first-fp><xocs:ref-last-lp>506</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0265"><xocs:ref-normalized-surname>CAMPBELL</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>77</xocs:ref-first-fp><xocs:ref-last-lp>92</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0270"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>520</xocs:ref-first-fp><xocs:ref-last-lp>526</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0275"><xocs:ref-normalized-surname>MIRAUCOURT</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>e1116</xocs:ref-first-fp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0280"><xocs:ref-normalized-surname>SLOANE</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>470</xocs:ref-first-fp><xocs:ref-last-lp>475</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0285"><xocs:ref-normalized-surname>BHARALI</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>11539</xocs:ref-first-fp><xocs:ref-last-lp>11544</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0290"><xocs:ref-normalized-surname>ROY</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>279</xocs:ref-first-fp><xocs:ref-last-lp>284</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0295"><xocs:ref-normalized-surname>LEDEBOER</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>PROCEEDINGS11THWORLDCONGRESSPAIN</xocs:ref-normalized-srctitle><xocs:ref-normalized-article-title>PACLITAXELINDUCEDMECHANICALALLODYNIAINRATSINHIBITEDBYSPINALDELIVERYPLASMIDDNAENCODINGINTERLEUKIN10</xocs:ref-normalized-article-title></xocs:ref-info><xocs:ref-info refid="rf0300"><xocs:ref-normalized-surname>MILLIGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>9</xocs:ref-first-fp><xocs:ref-last-lp>22</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:refkeys><xocs:refkey3>DENGLERX2013X209</xocs:refkey3><xocs:refkey4lp>DENGLERX2013X209X224</xocs:refkey4lp><xocs:refkey4ai>DENGLERX2013X209XE</xocs:refkey4ai><xocs:refkey5>DENGLERX2013X209X224XE</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-03-20T21:28:32Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>Author</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by-nc-nd/3.0/</xocs:oa-user-license></xocs:open-access><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0168-3659(13)00152-1</xocs:pii-formatted><xocs:pii-unformatted>S0168365913001521</xocs:pii-unformatted><xocs:eid>1-s2.0-S0168365913001521</xocs:eid><xocs:doi>10.1016/j.jconrel.2013.03.009</xocs:doi><xocs:cid>271103</xocs:cid><xocs:timestamp>2014-09-09T02:15:30.692888-04:00</xocs:timestamp><xocs:cover-date-start>2013-06-10</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NIH</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0168365913001521-main.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/MAIN/application/pdf/aaa0cea6b5f6518c1b055f50daf729f9/main.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/MAIN/application/pdf/aaa0cea6b5f6518c1b055f50daf729f9/main.pdf</xocs:ucs-locator><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>4173516</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>16</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0168365913001521-main_1.png</xocs:attachment-eid><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/PREVIEW/image/png/31284088cb486e9991fe8b988f1bf6e1/main_1.png</xocs:ucs-locator><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/PREVIEW/image/png/31284088cb486e9991fe8b988f1bf6e1/main_1.png</xocs:ucs-locator><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>62670</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr8_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr8/HIGHRES/image/jpeg/944e2f43b8054c0aa8c53fecee592c18/gr8_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr8/HIGHRES/image/jpeg/944e2f43b8054c0aa8c53fecee592c18/gr8_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>2449554</xocs:filesize><xocs:pixel-height>2523</xocs:pixel-height><xocs:pixel-width>3574</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr7_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr7/HIGHRES/image/jpeg/6306523101561d514785d9bb153fc292/gr7_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr7/HIGHRES/image/jpeg/6306523101561d514785d9bb153fc292/gr7_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>534449</xocs:filesize><xocs:pixel-height>3127</xocs:pixel-height><xocs:pixel-width>1612</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr6_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr6/HIGHRES/image/jpeg/8e2d0545ae5638ff6467549a677c0552/gr6_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr6/HIGHRES/image/jpeg/8e2d0545ae5638ff6467549a677c0552/gr6_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>664185</xocs:filesize><xocs:pixel-height>2225</xocs:pixel-height><xocs:pixel-width>3127</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr5_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr5/HIGHRES/image/jpeg/747ff64523c51e3150627e687d98c18e/gr5_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr5/HIGHRES/image/jpeg/747ff64523c51e3150627e687d98c18e/gr5_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>284664</xocs:filesize><xocs:pixel-height>1163</xocs:pixel-height><xocs:pixel-width>2761</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr4_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr4/HIGHRES/image/jpeg/5a5280bc13fc39ad34127982a90716f9/gr4_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr4/HIGHRES/image/jpeg/5a5280bc13fc39ad34127982a90716f9/gr4_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>1457136</xocs:filesize><xocs:pixel-height>3514</xocs:pixel-height><xocs:pixel-width>2341</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr3_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr3/HIGHRES/image/jpeg/5cfe25864a75495174d9915d1370038c/gr3_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr3/HIGHRES/image/jpeg/5cfe25864a75495174d9915d1370038c/gr3_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>932626</xocs:filesize><xocs:pixel-height>3478</xocs:pixel-height><xocs:pixel-width>3031</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr2/HIGHRES/image/jpeg/a969c5cdc4e74a4be046081a1232d756/gr2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr2/HIGHRES/image/jpeg/a969c5cdc4e74a4be046081a1232d756/gr2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>360448</xocs:filesize><xocs:pixel-height>999</xocs:pixel-height><xocs:pixel-width>1712</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr1/HIGHRES/image/jpeg/e1c496979ae2b77190bd58b3e1a78a24/gr1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr1/HIGHRES/image/jpeg/e1c496979ae2b77190bd58b3e1a78a24/gr1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>990595</xocs:filesize><xocs:pixel-height>3026</xocs:pixel-height><xocs:pixel-width>3054</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx2/HIGHRES/image/jpeg/0d1949239e6f256fd8ee757f11c59b4b/fx2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx2/HIGHRES/image/jpeg/0d1949239e6f256fd8ee757f11c59b4b/fx2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx2</xocs:file-basename><xocs:filename>fx2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>757454</xocs:filesize><xocs:pixel-height>2000</xocs:pixel-height><xocs:pixel-width>3605</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx1/HIGHRES/image/jpeg/f04aeeda62ae7191198e2065a496f940/fx1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx1/HIGHRES/image/jpeg/f04aeeda62ae7191198e2065a496f940/fx1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>336442</xocs:filesize><xocs:pixel-height>781</xocs:pixel-height><xocs:pixel-width>2213</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr8.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr8/DOWNSAMPLED/image/jpeg/0de2422d4c61e0541c67d6b6227d35cb/gr8.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr8/DOWNSAMPLED/image/jpeg/0de2422d4c61e0541c67d6b6227d35cb/gr8.jpg</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>177160</xocs:filesize><xocs:pixel-height>570</xocs:pixel-height><xocs:pixel-width>807</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr7.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr7/DOWNSAMPLED/image/jpeg/04183851b20581ec14c5a35fcc5c3dfc/gr7.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr7/DOWNSAMPLED/image/jpeg/04183851b20581ec14c5a35fcc5c3dfc/gr7.jpg</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>74505</xocs:filesize><xocs:pixel-height>706</xocs:pixel-height><xocs:pixel-width>364</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr6.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr6/DOWNSAMPLED/image/jpeg/1b879cfdea3025af4c74440901d069eb/gr6.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr6/DOWNSAMPLED/image/jpeg/1b879cfdea3025af4c74440901d069eb/gr6.jpg</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>65066</xocs:filesize><xocs:pixel-height>502</xocs:pixel-height><xocs:pixel-width>706</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr5.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr5/DOWNSAMPLED/image/jpeg/fd289281e4e8fe554e85d8386a2399c9/gr5.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr5/DOWNSAMPLED/image/jpeg/fd289281e4e8fe554e85d8386a2399c9/gr5.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>29161</xocs:filesize><xocs:pixel-height>262</xocs:pixel-height><xocs:pixel-width>623</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr4.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr4/DOWNSAMPLED/image/jpeg/367af41eb2912fcf82982baea2eac354/gr4.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr4/DOWNSAMPLED/image/jpeg/367af41eb2912fcf82982baea2eac354/gr4.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>118568</xocs:filesize><xocs:pixel-height>794</xocs:pixel-height><xocs:pixel-width>529</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr3.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr3/DOWNSAMPLED/image/jpeg/ea819147e3168d168029a3ec281c8453/gr3.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr3/DOWNSAMPLED/image/jpeg/ea819147e3168d168029a3ec281c8453/gr3.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>114599</xocs:filesize><xocs:pixel-height>786</xocs:pixel-height><xocs:pixel-width>685</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr2/DOWNSAMPLED/image/jpeg/ff1602aea8973d3ef19a84dd07ed6fa7/gr2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr2/DOWNSAMPLED/image/jpeg/ff1602aea8973d3ef19a84dd07ed6fa7/gr2.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>37787</xocs:filesize><xocs:pixel-height>225</xocs:pixel-height><xocs:pixel-width>386</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr1/DOWNSAMPLED/image/jpeg/4ecad3364142ce9bd85be54a0b8675b3/gr1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr1/DOWNSAMPLED/image/jpeg/4ecad3364142ce9bd85be54a0b8675b3/gr1.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>96320</xocs:filesize><xocs:pixel-height>684</xocs:pixel-height><xocs:pixel-width>690</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx2/DOWNSAMPLED/image/jpeg/fad3f7bf41322cfebd4d7d7dbfd13d14/fx2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx2/DOWNSAMPLED/image/jpeg/fad3f7bf41322cfebd4d7d7dbfd13d14/fx2.jpg</xocs:ucs-locator><xocs:file-basename>fx2</xocs:file-basename><xocs:filename>fx2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>86785</xocs:filesize><xocs:pixel-height>452</xocs:pixel-height><xocs:pixel-width>814</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx1/DOWNSAMPLED/image/jpeg/ceb92931f063920f6730a9c98359e0a5/fx1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx1/DOWNSAMPLED/image/jpeg/ceb92931f063920f6730a9c98359e0a5/fx1.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>42805</xocs:filesize><xocs:pixel-height>176</xocs:pixel-height><xocs:pixel-width>500</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr8.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr8/THUMBNAIL/image/gif/72f9f9cbe86c58c044f65c00763c046f/gr8.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr8/THUMBNAIL/image/gif/72f9f9cbe86c58c044f65c00763c046f/gr8.sml</xocs:ucs-locator><xocs:file-basename>gr8</xocs:file-basename><xocs:filename>gr8.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>11381</xocs:filesize><xocs:pixel-height>155</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr7.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr7/THUMBNAIL/image/gif/bcb74b9d40c300c6ac6282ecd6c9de90/gr7.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr7/THUMBNAIL/image/gif/bcb74b9d40c300c6ac6282ecd6c9de90/gr7.sml</xocs:ucs-locator><xocs:file-basename>gr7</xocs:file-basename><xocs:filename>gr7.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3210</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>84</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr6.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr6/THUMBNAIL/image/gif/e0e48ab237e19d123cb5213f1183abfd/gr6.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr6/THUMBNAIL/image/gif/e0e48ab237e19d123cb5213f1183abfd/gr6.sml</xocs:ucs-locator><xocs:file-basename>gr6</xocs:file-basename><xocs:filename>gr6.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7863</xocs:filesize><xocs:pixel-height>156</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr5.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr5/THUMBNAIL/image/gif/18a54b6c745cc7d4bb67f4fc94812928/gr5.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr5/THUMBNAIL/image/gif/18a54b6c745cc7d4bb67f4fc94812928/gr5.sml</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2803</xocs:filesize><xocs:pixel-height>92</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr4.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr4/THUMBNAIL/image/gif/6af063401d53dfaf208008e30e594848/gr4.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr4/THUMBNAIL/image/gif/6af063401d53dfaf208008e30e594848/gr4.sml</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>8504</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>109</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr3.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr3/THUMBNAIL/image/gif/adff8d8fa6f7b9f15646738fb413d2d8/gr3.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr3/THUMBNAIL/image/gif/adff8d8fa6f7b9f15646738fb413d2d8/gr3.sml</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>4779</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>143</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr2/THUMBNAIL/image/gif/3a562190be63fdc34c4225ad137419fc/gr2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr2/THUMBNAIL/image/gif/3a562190be63fdc34c4225ad137419fc/gr2.sml</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6131</xocs:filesize><xocs:pixel-height>128</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-gr1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/gr1/THUMBNAIL/image/gif/05cd4a88a7071512dc5d1bac67274640/gr1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/gr1/THUMBNAIL/image/gif/05cd4a88a7071512dc5d1bac67274640/gr1.sml</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6986</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>165</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx2/THUMBNAIL/image/gif/aea14bac21a8810b5df0b97c455f7f44/fx2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx2/THUMBNAIL/image/gif/aea14bac21a8810b5df0b97c455f7f44/fx2.sml</xocs:ucs-locator><xocs:file-basename>fx2</xocs:file-basename><xocs:filename>fx2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>7513</xocs:filesize><xocs:pixel-height>121</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913001521-fx1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913001521/fx1/THUMBNAIL/image/gif/e07b8f8c6e311acbdb6af371a04b06a8/fx1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913001521/fx1/THUMBNAIL/image/gif/e07b8f8c6e311acbdb6af371a04b06a8/fx1.sml</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6845</xocs:filesize><xocs:pixel-height>77</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc></xocs:meta><xocs:serial-item><article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>COREL</jid><aid>6657</aid><ce:pii>S0168-3659(13)00152-1</ce:pii><ce:doi>10.1016/j.jconrel.2013.03.009</ce:doi><ce:copyright type="full-transfer" year="2013">Elsevier B.V.</ce:copyright></item-info><ce:floats><ce:figure id="f0010"><ce:label>Fig. 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0015" view="all">Characterizations of protocells. (A) TEM image of mesoporous silica nanoparticles; scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>50<ce:hsp sp="0.25"/>nm. (C) Inset: Cryogenic TEM image revealing the liposome bilayer that is ~<ce:hsp sp="0.10"/>4<ce:hsp sp="0.25"/>nm thick (white arrows); scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>50<ce:hsp sp="0.25"/>nm. (B) Particle size distribution of 15<ce:hsp sp="0.25"/>mol% APTES modified mesoporous silica cores as measured by dynamic light scattering. The average particle diameter of the mesoporous silica cores is 230-nm with a rather wide particle size distribution reflecting that of the aerosol generator. The surface of the mesoporous silica core in these studies was chemically modified with 15<ce:hsp sp="0.25"/>mol% aminopropyltriethoxysilane (APTES) to impart a positive surface charge (24<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>5<ce:hsp sp="0.25"/>mV in 0.5<ce:hsp sp="0.10"/>× PBS) that increases loading efficiency of negatively charged cargo. When fused with positively charged DOTAP/DOPC or neutrally charged DOPC-based liposomes, the surface charge was measured in 0.5<ce:hsp sp="0.10"/>× PBS to be 4.5<ce:hsp sp="0.25"/>mV<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>2.2<ce:hsp sp="0.25"/>mV or −<ce:hsp sp="0.10"/>11.4<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>3.6<ce:hsp sp="0.25"/>mV, respectively. (D) Nitrogen sorption isotherm of 15% aminated silica nanoparticles is a type IV isotherm with a narrow hysteresis loop, typical of a 2D hexagonal mesoporous silica. (E) The pore diameter was determined to be 2–5<ce:hsp sp="0.25"/>nm with a narrow distribution using the Barrett–Joyner–Halenda (BJH) model. The Brunauer–Emmett–Teller (BET) surface area is ~<ce:hsp sp="0.10"/>935m<ce:sup loc="post">2</ce:sup>/g, with a pore volume ~<ce:hsp sp="0.10"/>0.48<ce:hsp sp="0.25"/>cm<ce:sup loc="post">3</ce:sup>/g and the porosity of 0.52. (F) DOPC protocells and (G) DOTAP:Chol protocells examined from 1 to 168<ce:hsp sp="0.25"/>h at pH<ce:hsp sp="0.25"/>6 and 7.4 (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 samples/pH values/timepoint). The negatively charged fluorophore, dextran tetramethylrhodamine (DexRho) loaded protocells served as anionic cargo. For DOPC protocells, cargo release time-dependently increased to 24<ce:hsp sp="0.25"/>h and remained relatively stable (~<ce:hsp sp="0.10"/>45) thereafter through 168<ce:hsp sp="0.25"/>h (F<ce:inf loc="post">(7,32)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>8.728; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001), with initially greater cargo release at pH<ce:hsp sp="0.25"/>7.4 than at pH<ce:hsp sp="0.25"/>6.0 (F<ce:inf loc="post">(1,32)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>51.0; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001). DOTAP:Chol protocell cargo revealed a similar release pattern to DOPC protocells with the exception that increased cargo from DOTAP:Chol continued to increase through 48<ce:hsp sp="0.25"/>h (F<ce:inf loc="post">(7,32)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>6.98; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001) with release appearing consistent thereafter. Also similar to DOPC, cargo release from DOTAP:Chol protocells is initially greater at pH<ce:hsp sp="0.25"/>7.4 compared to pH<ce:hsp sp="0.25"/>6.0 (F<ce:inf loc="post">(1,32)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>15.42; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001). Thus these data suggest that cargo retention is greatest at pH<ce:hsp sp="0.25"/>6.0 in both DOPC and DOTAP:Chol formulated protocells. Note: while standard error of the mean (SEM) is provided indicating sample variance, % confidence interval (%CV) is additionally provided along the X-axis. The pattern of greater cargo release that is somewhat pH sensitive for the first several days suggests that time and pH may be important factors that influence initial drug-delivery kinetics.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0010"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 2</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0020" view="all">Cells remain highly viable following application of DOTAP:Chol and DOPC protocells containing pDNA-IL-10-GFP. Cells were incubated for 24<ce:hsp sp="0.25"/>h with DOTAP:Chol or DOPC protocells loaded with pDNA-IL-10-GFP or blank control protocells (no pDNA) at varying concentrations across a 50-fold dose range, 500, 50, 25 and 10<ce:hsp sp="0.25"/>μg/ml. Dead cells were identified by flow cytometry after staining with ethidium-homodimer-1. Results are representative of the percentage of gated cells (average of 4 experiments) compared to untreated control cells, **p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; and ***p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0015"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 3</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0025" view="all"><ce:italic>In vivo</ce:italic> characterization of the biocompatibility between DOTAP:Chol and DOPC protocells. For clarity, protocell type (DOTAP <ce:italic>vs.</ce:italic> DOPC) is separated and represented in graphs identified as DOTAP or DOPC data, while the identical vehicle-treated group (assessed alongside the protocell-treatment groups during experimentation) is represented with both the DOTAP- and DOPC-treated animals. (A–D) Baseline (BL) threshold responses of both hindpaws (left and right) between all animal groups were similar (F<ce:inf loc="post">(9,20)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.288; p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.97). (A, B) Following i.t. injection with either 1 or 0.01<ce:hsp sp="0.25"/>mg of DOTAP:Chol or vehicle, left hindpaw threshold responses remained unchanged throughout the timecourse (0.5, 1, 2, 3, 24, 48 and 72<ce:hsp sp="0.25"/>h) (F(<ce:inf loc="post">6,24)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>1.63; p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.181), however, right hindpaw thresholds were moderately reduced (F(<ce:inf loc="post">6,24)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3.45; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05). Post-hoc analysis revealed that thresholds responses 30<ce:hsp sp="0.25"/>min after DOTAP protocell injection were significantly lower than vehicle treated animals (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05). (C, D) For DOPC-treated animals, while an overall decrease in thresholds was not observed across the timecourse in left (F<ce:inf loc="post">(24,60)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>1.88; p<ce:hsp sp="0.25"/>&gt;<ce:hsp sp="0.25"/>0.05) or right hindpaws (F<ce:inf loc="post">(24,60)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>1.01; p<ce:hsp sp="0.25"/>&gt;<ce:hsp sp="0.25"/>0.05), a small and significant decrease at 2<ce:hsp sp="0.25"/>h in both hindpaws was observed (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05). Throughout the 8-week observation, all animals exhibited normal grooming, activity, exploratory behavior and body weight gain following i.t. injection with DOTAP:Chol or DOPC protocells. (E) At BL, there was no significant difference in body weight between untreated (black triangles) and treated animals that received i.t. DOTAP:Chol (2<ce:hsp sp="0.25"/>weeks, solid gray circles; 4<ce:hsp sp="0.25"/>weeks, solid gray diamonds; 8<ce:hsp sp="0.25"/>weeks, solid gray squares) or DOPC protocells (2<ce:hsp sp="0.25"/>weeks, solid black circles; 4<ce:hsp sp="0.25"/>weeks, solid black diamonds; and 8<ce:hsp sp="0.25"/>weeks, solid black squares) (F<ce:inf loc="post">(6,14)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>2.837, p<ce:hsp sp="0.25"/>&gt;<ce:hsp sp="0.25"/>0.05). Consistent and normal gain in body weight compared to their BL levels was observed prior to sacrifice at 2<ce:hsp sp="0.25"/>weeks (F<ce:inf loc="post">(10,30)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3.02, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001), at 4<ce:hsp sp="0.25"/>week (F<ce:inf loc="post">(14,42)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>2.62, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001), and at 8<ce:hsp sp="0.25"/>weeks (F<ce:inf loc="post">(16,48)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3.65, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001) during an 8-wk observation period occurred in control animals and those receiving protocells by i.t. injection (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 per group). *p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; and #p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0020"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 4</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" view="all">Histological examination of DOTAP:Chol protocells with 18-bp FAM-labeled DNA cargo in the spinal cord. Fluorescent histological examination of spinal cord sections near the lumbar spinal cord injection site (segments L3–4) 8<ce:hsp sp="0.25"/>weeks after i.t. injection of DOTAP:Chol protocells loaded with DNA cargo (2<ce:hsp sp="0.25"/>μg). (A) Protocells containing DNA cargo (green; white arrow) are not colocalized with astroglia stained for glial fibrillary acidic protein, GFAP (red) and do not penetrate the spinal parenchyma, but are localized to the spinal pia and arachnoid matter. (B) Protocells localized to the peri-spinal meninges containing cells stained with the microglia/macrophage antigen expression protein, Cd11b (red). Colocalization of Cd11b with DNA cargo (green) is observed as yellow (white arrow). (C) There is no evidence of cellular death in tissue in contact with protocells, as indicated by the absence of positive staining for the apoptotic marker, activated Caspase 3 (red) while protocell-containing DNA cargo (green; white arrow) is clearly present in the peri-spinal meninges. (D) Confocal image identifying DOTAP:Chol protocell cargo of FAM-labeled DNA (green) in the peri-nuclear area (cell nuclei stained with DAPI; blue) of meningeal macrophage cells stained for the classic activation marker, EDI (red; white arrow) in the dorsal spinal cord meninges. Overlap reveals yellow cytoplasmic and peri-nuclear staining. All images are at 20<ce:hsp sp="0.10"/>×; scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>40<ce:hsp sp="0.25"/>μm. (E–F) Confocal images identifying single-stranded FITC-labeled DNA cargo (2<ce:hsp sp="0.25"/>μg) loaded onto DOTAP-formulated protocells with DOTAP labeled with Alexa-fluo 647, which is visualized only under UV light (red). (E) The confocal fluorescent images reveal the presence of protocell cargo (green DNA) and (F) DOTAP:Chol liposome (Alexa-fluo 647, far red) in meninges at the site 3<ce:hsp sp="0.25"/>days following intrathecal injection. (G) The identical tissue region collected with light differential interference contrast (DIC) and (H) an overlay of both fluorescent and DIC to verify co-localization of silica-supported DOTAP:chol and its DNA cargo. Images are 10<ce:hsp sp="0.10"/>×; scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>40<ce:hsp sp="0.25"/>μm.</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0025"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 5</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" view="all">The lipid bilayer formulation of the protocell determines the degree of spread throughout the CNS following an i.t. injection. Graphs are representative of the key data in the corresponding <ce:cross-ref refid="t0010" id="cf0005">Table 2</ce:cross-ref>. Fluorescent spectral signal from FAM-labeled 18-bp DNA cargo in cryostat-sliced tissue sections (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4) of DOTAP:Chol or DOPC protocell i.t. treated animals is compared to the spectra of background autofluorescence from naïve animals. (A) In the brain at 72<ce:hsp sp="0.25"/>h, no significant signal from FAM-tagged DNA delivered by either DOTAP:Chol or DOPC protocells was observed. However, by 8<ce:hsp sp="0.25"/>weeks, compared to DOTAP:Chol protocell treated tissue and autofluorescence, FAM-labeled DNA delivered by DOPC protocells had significantly increased (F<ce:inf loc="post">(2,6)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>8.60; p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.0173). (B) In the lumbar spinal cord, DNA delivered by both DOPC and DOTAP:Chol protocells was present at both 72<ce:hsp sp="0.25"/>h and 8<ce:hsp sp="0.25"/>weeks (FAM signal analysis <ce:italic>vs.</ce:italic> autofluorescence, F<ce:inf loc="post">(2,6)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>6.18; p<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>0.0348), with DNA levels at 72<ce:hsp sp="0.25"/>h significantly higher than those at 8<ce:hsp sp="0.25"/>weeks (F<ce:inf loc="post">(1,6)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>10.71; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.02).</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0030"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 6</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0040" view="all">DOTAP:Chol protocells improve cellular transfection of pDNA-IL10 transgene. (A, C) <ce:italic>In vitro</ce:italic> transfection of HEK cells with a DOTAP:Chol protocells loaded with a bicistronic plasmid containing the genes for both IL-10 and GFP by employing an internal ribosomal entry site, results in expression of both IL-10 and GFP. (B) DOTAP:Chol protocells loaded with pDNA-IL-10 without the GFP transgene and incubated in HEK cells result in robust IL-10 protein. (C; inset) DOTAP:Chol protocells loaded with the bicistronic plasmid, pDNA-IL-10/GFP resulting in functional transgene expression are observed under fluorescent microscopy with GFP-positive HEK cells and staining with antibody for IL-10 (red) reveals colocalization (yellow) (F<ce:inf loc="post">1,4</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>24.85; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001). (D) While DOTAP:Chol liposome without mesoporous silica core results in a significant increase in IL-10 protein expression in pDNA-IL-10<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>DOTAP treatment compared to no pDNA-IL-10 and pDNA-IL-10 alone (F<ce:inf loc="post">(2,9)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>426.6; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001), IL-10 protein levels from DOTAP liposomes<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>pDNAIL-10 remain 10-fold less than protein levels resulting from incubation with DOTAP:Chol protocell-pDNA-IL-10 (p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05). Secreted recombinant IL-10 from media samples (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4/condition) were collected 24<ce:hsp sp="0.25"/>h post-transfection and rat IL-10 protein was quantified using a rat IL-10 specific Quantikine™ ELISA kit. **p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01, ***p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>10<ce:hsp sp="0.25"/>μm in both A and inset.</ce:simple-para></ce:caption><ce:link locator="gr6" id="lk0035"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 7</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0045" view="all">Intrathecal (i.t.; peri-spinal in direct meningeal contact) delivery of DOTAP:Chol formulated protocells loaded with pDNA-IL-10 causes therapeutic reversal of allodynia. (A and B) At pre-treatment baseline (BL) values, no significant differences were observed in threshold responses of either hindpaw (left and right; p<ce:hsp sp="0.25"/>&gt;<ce:hsp sp="0.25"/>0.05). Following BL assessment, animals underwent a discrete CCI of the left sciatic nerve to produce neuropathy, and threshold values were reassessed 3 and 10<ce:hsp sp="0.25"/>days later when robust allodynia was observed compared to sham-treated controls (ipsilateral to CCI, F<ce:inf loc="post">(8,36)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4.94; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0004; contralateral to CCI, F<ce:inf loc="post">(8,36)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>19.89; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001). On Day 10 after CCI, rats then received an i.t. injection of DOTAP:Chol protocells loaded with pDNA cargo (10<ce:hsp sp="0.25"/>μg) encoding either IL-10 or non-encoding pDNA (as a gene therapy control), or vehicle (20<ce:hsp sp="0.25"/>μl isotonic saline). A significant bilateral reversal of allodynia reached significance on Day 12 after CCI (Day 2 after i.t. injection) that reliably continued through Day 22, with partial reversal observed on Day 24 (ipsilateral hindpaw: F<ce:inf loc="post">(4,108)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>44.91; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001, contralateral hindpaw: F<ce:inf loc="post">(4,108)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>85.09; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001). Black squares represent CCI<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>i.t. pDNA-IL-10 (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>7), black triangles represent non-coding CCI<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>pDNA (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>5), black circles represent CCI<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>saline (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3), open triangles represent sham (no CCI)<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>i.t. non-coding pDNA (‘control pDNA’, n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>5), and open circles represent sham<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>vehicle (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). Black arrow indicates i.t. injection, ‘Inj’; *p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; and ***p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001. (C) Nitric oxide (NO) production was assessed to determine cell-stress responses following a 24<ce:hsp sp="0.25"/>hr incubation with DOTAP:Chol protocells loaded with pDNA-IL-10 cargo in the macrophage cell line, Raw 264.7 (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4–5<ce:hsp sp="0.25"/>wells/condition). LPS, that classically induces cell stress pathways and stimulates NO production (black bar), was used as a positive control. NO levels in cell supernatant from cells without treatment (‘No Tx’, white bar) to assess background levels of NO, DOTAP:Chol protocells (‘PC’, hatched bar), or constituents of protocells such as the mesoporous silica core (‘Core’, 500<ce:hsp sp="0.25"/>μg; horizontal striped bar) or Dotap:Chol lipid (‘Lipid’, vertical striped bars) were assessed for NO levels. While no significant increase in NO production was observed in cell supernatants following treatment with protocells or its constituents compared to the no treatment controls, LPS treated cells revealed significantly elevated NO levels compared to core, lipid or PC treatment (F<ce:inf loc="post">(4,14)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>321.8; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001).</ce:simple-para></ce:caption><ce:link locator="gr7" id="lk0040"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 8</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0050" view="all">Schematic representation of the mesoporous silica particle-supported lipid bilayer representing the theoretical loading of the diagnostic molecules and the plasmid DNA-IL-10 gene (pDNA-IL-10) used in this report. The typical 2D hexagonal mesoporous silica is depicted. Supercoiled pDNA-IL-10 (~<ce:hsp sp="0.10"/>50<ce:hsp sp="0.25"/>nm) is primarily in between the liposome and at the surface of the protocell, while smaller diagnostic molecules (18-bp DNA and DexRho) load into the silica pores as well as interact with the liposomes. Chemical structures for DOTAP, cholesterol, DOPC and DexRho are provided.</ce:simple-para></ce:caption><ce:link locator="gr8" id="lk0045"/></ce:figure><ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="t0005" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 1</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0055" view="all">Characterization of anionic DexRho-loaded DOPC and DOTAP:Chol protocells at various pH values over time. To fully characterize the stability of cargo release at extreme pH values as well as at physiologically relevant pH values, DexRho cargo release was examined at discrete timepoints at pH values ranging from 2 to 10. The samples (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3/conditions) were averaged (mean) and the sample variance is presented (SEM) as well as the sample % coefficient of variation (%CV) that provides comparisons between independent datasets that are sensitive to small changes in the sample means. Compared to DOTAP:Chol formulated protocells, the cargo from DOPC formulated protocells at pH<ce:hsp sp="0.25"/>2 is retained across time, while similar to DOTAP:Chol, the greatest cargo release is observed at pH<ce:hsp sp="0.25"/>10 that moderately increases with time. Thus, both protocell formulation (DOTAP:Chol and DOPC) and pH significantly influence cargo release over time (F<ce:inf loc="post">(77,192)</ce:inf><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>1.60; p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01).</ce:simple-para></ce:caption><tgroup cols="17"><colspec colname="col1"/><colspec colname="col2"/><colspec colname="col3"/><colspec colname="col4"/><colspec colname="col5"/><colspec colname="col6"/><colspec colname="col7"/><colspec colname="col8"/><colspec colname="col9"/><colspec colname="col10"/><colspec colname="col11"/><colspec colname="col12"/><colspec colname="col13"/><colspec colname="col14"/><colspec colname="col15"/><colspec colname="col16"/><colspec colname="col17"/><thead><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1"/><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col5" align="left">pH<hsp sp="0.25"/>2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col6" nameend="col9" align="left">pH<hsp sp="0.25"/>4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col10" nameend="col13" align="left">pH<hsp sp="0.25"/>8</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col14" nameend="col17" align="left">pH<hsp sp="0.25"/>10</entry></row><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">Lipid formulation</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col2" nameend="col3" align="left">DOTAP:Chol</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5" align="left">DOPC</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col6" nameend="col7" align="left">DOTAP:Chol</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col8" nameend="col9" align="left">DOPC</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col10" nameend="col11" align="left">DOTAP:Chol</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col12" nameend="col13" align="left">DOPC</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col14" nameend="col15" align="left">DOTAP:Chol</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col16" nameend="col17" align="left">DOPC</entry></row><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">Hours</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="left">SEM/%CV</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="left">Ave</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="left">SEM/%CV</entry></row></thead><tbody><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">1</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">30.22</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">5.01/23.36</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">18.90</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">7.57/56.45</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">30.12</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">1.61/7.55</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">24.5.4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">6.62/38.03</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">38.41</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">6.24/22.92</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">37.97</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">0.68/2.53</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">37.20</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">7.72/29.27</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">50.53</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">5.64/15.73</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">3</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">31.09</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">2.18/9.87</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">24.36</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">2.34/13.54</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">34.45</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">1.31/5.38</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">23.33</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">8.48/51.30</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">47.26</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">5.68/16.96</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">38.38</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">4.53/16.65</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">47.86</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">6.53/19.24</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">56.54</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">7.39/18.82</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">6</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">23.47</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">0.64/3.86</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">22.23</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">2.01/12.72</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">31.94</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">6.39/28.19</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">34.43</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">7.18/29.40</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">42.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">6.94/22.93</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">48.02</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">4.38/12.88</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">48.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">9.24/26.76</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">66.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">5.82/12.3</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">24</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">23.15</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">0.05/0.32</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">18.99</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">1.23/9.12</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">38.75</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">3.83/13.94</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">35.41</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">7.69/30.60</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">39.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">7.68/27.28</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">51.97</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">4.63/12.57</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">67.07</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">8.10/17.03</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">79.69</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">10.95/9.38</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">48</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">26.35</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">3.24/17.35</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">17.09</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">2.45/20.23</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">45.58</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">2.26/7.0</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">39.07</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">6.86/24.75</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">43.60</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">7.30/23.62</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">54.93</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">9.17/23.54</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">71.40</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">12.58/24.84</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">77.16</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">7.26/13.26</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">72</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">28.42</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">1.32/6.53</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">17.92</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">3.23/25.39</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">45.82</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">2.22/6.84</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">29.09</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">8.11/39.29</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">47.39</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">8.68/25.83</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">42.88</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">2.94/9.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">81.17</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">11.44/19.87</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">77.69</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">11.36/20.61</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">96</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">31.07</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">4.53/20.56</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">17.04</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">2.04/16.87</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">40.88</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">1.07/3.68</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">39.47</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">8.58/30.64</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">52.06</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">8.69/53.53</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">51.81</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">11.92/32.44</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">78.29</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">13.38/24.11</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">73.45</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">1.49/2.85</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">168</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="char" char=".">38.60</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="char" char="/">2.30/8.38</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">12.05</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="char" char="/">4.75/55.63</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="char" char=".">42.05</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char="/">3.05/10.23</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="char" char=".">28.49</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col9" align="char" char="/">7.69/38.06</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col10" align="char" char=".">50.45</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col11" align="char" char="/">6.49/18.13</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col12" align="char" char=".">50.50</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col13" align="char" char="/">10.29/28.73</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col14" align="char" char=".">81.48</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col15" align="char" char="/">11.36/19.66</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col16" align="char" char=".">91.17</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col17" align="char" char="/">9.49/14.67</entry></row></tbody></tgroup></ce:table><ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="t0010" colsep="0" rowsep="0"><ce:label><ce:bold>Table 2</ce:bold></ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0060" view="all">Values (1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>E<ce:hsp sp="0.10"/>−<ce:hsp sp="0.10"/>04) of each anatomical region are an average of computer-generated spectral analyses taken from 4 separate images of four 10<ce:hsp sp="0.25"/>μm cryostat sliced tissue sections. Yellow boxes indicate those areas in which the signal from FAM-labeled DNA cargo reached levels that were significantly higher than control autofluorescence for that tissue. Asterisks indicate the amount of significance. At 72<ce:hsp sp="0.25"/>h and 8<ce:hsp sp="0.25"/>weeks, very low levels of DOPC or DOTAP:Chol protocells were detected in the blood (data not shown), thymus, spleen, liver and kidney, while measurable amounts of DOTAP:Chol and DOPC were detected in the CNS.</ce:simple-para></ce:caption><ce:link id="lk0005" locator="fx2"/><ce:legend><ce:simple-para id="sp0065" view="all">*p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05.</ce:simple-para><ce:simple-para id="sp0070" view="all">**p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01.</ce:simple-para><ce:simple-para id="sp0075" view="all">***p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.0001.</ce:simple-para></ce:legend></ce:table></ce:floats><head><ce:title id="ti0005">Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Ellen C.</ce:given-name><ce:surname>Dengler</ce:surname><ce:cross-ref refid="af0005" id="cf0010"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">edengler@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0010"><ce:given-name>Juewen</ce:given-name><ce:surname>Liu</ce:surname><ce:cross-ref refid="af0010" id="cf0015"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:e-address id="em0010" type="email">liujuewen@gmail.com</ce:e-address></ce:author><ce:author id="au0015"><ce:given-name>Audra</ce:given-name><ce:surname>Kerwin</ce:surname><ce:cross-ref refid="af0005" id="cf0020"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0015" type="email">akerwin@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0020"><ce:given-name>Sergio</ce:given-name><ce:surname>Torres</ce:surname><ce:cross-ref refid="af0005" id="cf0025"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0020" type="email">sertorres@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0025"><ce:given-name>Clara M.</ce:given-name><ce:surname>Olcott</ce:surname><ce:cross-ref refid="af0005" id="cf0030"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0025" type="email">colcott@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0030"><ce:given-name>Brandi N.</ce:given-name><ce:surname>Bowman</ce:surname><ce:cross-ref refid="af0005" id="cf0035"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0030" type="email">bbowman@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0035"><ce:given-name>Leisha</ce:given-name><ce:surname>Armijo</ce:surname><ce:cross-ref refid="af0005" id="cf0040"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0035" type="email">liesha.armijo@gmail.com</ce:e-address></ce:author><ce:author id="au0040"><ce:given-name>Katherine</ce:given-name><ce:surname>Gentry</ce:surname><ce:cross-ref refid="af0015" id="cf0045"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:e-address id="em0040" type="email">k8gentry@gmail.com</ce:e-address></ce:author><ce:author id="au0045"><ce:given-name>Jenny</ce:given-name><ce:surname>Wilkerson</ce:surname><ce:cross-ref refid="af0005" id="cf0050"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0045" type="email">jlwilkerson@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0050"><ce:given-name>James</ce:given-name><ce:surname>Wallace</ce:surname><ce:cross-ref refid="af0005" id="cf0055"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:e-address id="em0050" type="email">jwallace@salud.unm.edu</ce:e-address></ce:author><ce:author id="au0055"><ce:given-name>Xingmao</ce:given-name><ce:surname>Jiang</ce:surname><ce:cross-ref refid="af0010" id="cf0060"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:e-address id="em0055" type="email">jiangxm@unm.edu</ce:e-address></ce:author><ce:author id="au0060"><ce:given-name>Eric C.</ce:given-name><ce:surname>Carnes</ce:surname><ce:cross-ref refid="af0010" id="cf0065"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:e-address id="em0060" type="email">eric.carnes@gmail.com</ce:e-address></ce:author><ce:author id="au0065"><ce:given-name>C. Jeffrey</ce:given-name><ce:surname>Brinker</ce:surname><ce:cross-ref refid="af0010" id="cf0070"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:e-address id="em0065" type="email">cjbrink@sandia.gov</ce:e-address></ce:author><ce:author id="au0070"><ce:given-name>Erin D.</ce:given-name><ce:surname>Milligan</ce:surname><ce:cross-ref refid="af0020" id="cf0075"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0080"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0070" type="email">EMilligan@salud.unm.edu</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">Department of Neurosciences, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA</ce:textfn><sa:affiliation><sa:organization>Department of Neurosciences</sa:organization><sa:organization>Health Sciences Center</sa:organization><sa:organization>University of New Mexico</sa:organization><sa:city>Albuquerque</sa:city><sa:state>NM</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Department of Chemical and Nuclear Engineering, University of New Mexico, Albuquerque, NM, USA</ce:textfn><sa:affiliation><sa:organization>Department of Chemical and Nuclear Engineering</sa:organization><sa:organization>University of New Mexico</sa:organization><sa:city>Albuquerque</sa:city><sa:state>NM</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">Department of Anesthesiology and Critical Care Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA</ce:textfn><sa:affiliation><sa:organization>Department of Anesthesiology and Critical Care Medicine</sa:organization><sa:organization>Health Sciences Center</sa:organization><sa:organization>University of New Mexico</sa:organization><sa:city>Albuquerque</sa:city><sa:state>NM</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0020"><ce:label>d</ce:label><ce:textfn id="tn0020">Department of Neurosciences, Health Sciences Center, School of Medicine, University of New Mexico, Albuquerque, NM 87131-5223, USA</ce:textfn><sa:affiliation><sa:organization>Department of Neurosciences</sa:organization><sa:organization>Health Sciences Center</sa:organization><sa:organization>School of Medicine</sa:organization><sa:organization>University of New Mexico</sa:organization><sa:city>Albuquerque</sa:city><sa:state>NM</sa:state><sa:postal-code>87131-5223</sa:postal-code><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Corresponding author. Tel.: +<ce:hsp sp="0.10"/>1 505 272 8103; fax: +<ce:hsp sp="0.10"/>1 505 272 8082.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="8" month="6" year="2012"/><ce:date-accepted day="8" month="3" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">Amorphous mesoporous silica nanoparticles (‘protocells’) that support surface lipid bilayers recently characterized <ce:italic>in vitro</ce:italic> as carrier constructs for small drug and DNA delivery are reported here as highly biocompatible both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>, involving the brain and spinal cord following spinal delivery into the lumbosacral subarachnoid space (intrathecal; i.t.). Specifically, positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)–cholesterol (DOTAP:Chol) liposome-formulated protocells revealed stable <ce:italic>in vitro</ce:italic> cargo release kinetics and cellular interleukin-10 (IL-10) transgene transfection. Recent approaches using synthetic non-viral vector platforms to deliver the pain-suppressive therapeutic transgene, IL-10, to the spinal subarachnoid space have yielded promising results in animal models of peripheral neuropathy, a condition involving aberrant neuronal communication within sensory pathways in the nervous system.</ce:simple-para><ce:simple-para id="sp0010" view="all">Non-viral drug and gene delivery protocell platforms offer potential flexibility because cargo release-rates can be pH-dependent. We report here that i.t. delivery of protocells, with modified chemistry supporting a surface coating of DOTAP:Chol liposomes and containing the IL-10 transgene, results in functional suppression of pain-related behavior in rats for extended periods. This study is the first demonstration that protocell vectors offer amenable and enduring <ce:italic>in vivo</ce:italic> biological characteristics that can be applied to spinal gene delivery.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical" id="ab0010" view="all"><ce:section-title id="st0010">Graphical abstract</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0080" view="all"><ce:display><ce:figure id="f0005"><ce:link locator="fx1" id="lk0050"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" view="all" class="keyword"><ce:section-title id="st0015">Keywords</ce:section-title><ce:keyword id="kw0050"><ce:text id="tx0015">Interleukin-10 cytokine</ce:text></ce:keyword><ce:keyword id="kw0060"><ce:text id="tx0025">Gene delivery</ce:text></ce:keyword><ce:keyword id="kw0065"><ce:text id="tx0030">Biocompatibility</ce:text></ce:keyword><ce:keyword id="kw0070"><ce:text id="tx0035">Neuropathic pain</ce:text></ce:keyword><ce:keyword id="kw0075"><ce:text id="tx0040">Cell and tissue viability</ce:text></ce:keyword><ce:keyword id="kw0080"><ce:text id="tx0045">Non-viral vector</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0020">Introduction</ce:section-title><ce:para id="p0005" view="all">The development of synthetic non-viral vectors for gene therapeutic purposes has steadily increased during the past 10<ce:hsp sp="0.25"/>years, an effort that is reflected by increased non-viral gene therapeutic clinical trials worldwide <ce:cross-refs refid="bb0005 bb0010" id="cf0085">[1,2]</ce:cross-refs>. While viral vectors are superior in gene transfection efficiency, non-viral gene transfer systems are associated with less safety concerns. The application of central nervous system (CNS) non-viral gene transfer to express therapeutic proteins is significantly underexplored in light of the broad-ranging therapeutic potential in controlling a host of neurological diseases. The arsenal of potential clinical gene delivery platforms includes cationic lipids and peptides, co-polymers, polymeric micelles, and modified silica nanoparticles <ce:cross-refs refid="bb0015 bb0020 bb0025" id="cf0090">[3–5]</ce:cross-refs>. Indeed, a significant amount of progress toward our understanding and utilizing mesoporous silica nanoparticles (MSN) for controlled drug and gene release, while optimizing biocompatibility, has occurred in recent years <ce:cross-ref refid="bb0030" id="cf0095">[6]</ce:cross-ref>. Silicas are present in crystalline and non-crystalline (amorphous) forms, with amorphous silica occurring either naturally or are synthesized. While crystalline silica is widely associated with adverse health effects including silicosis that involves proinflammatory cytokine-mediated pathogenesis, virtually no toxicity has been identified with synthetic amorphous silicas at moderate doses <ce:cross-refs refid="bb0035 bb0040" id="cf0100">[7,8]</ce:cross-refs>. Therefore, synthetic amorphous silicas have been explored in biomedical applications including targeted drug delivery for cancer chemotherapeutics and DNA delivery for gene therapy <ce:cross-refs refid="bb0045 bb0050" id="cf0105">[9,10]</ce:cross-refs>. The major advantage of using synthesized MSNs is that their surface can be chemically modified resulting in improvements in their drug cargo capacity as well as facilitation of tunable release rates which further enhances their biocompatibility and functional capabilities <ce:cross-ref refid="bb0055" id="cf0110">[11]</ce:cross-ref>.</ce:para><ce:para id="p0010" view="all">Mesoporous silicas contain a porous structure with hundreds of channels referred to as mesopores, which are able to adsorb bioactive molecules <ce:cross-ref refid="bb0055" id="cf0115">[11]</ce:cross-ref>. The properties of MSNs include a large surface area (&gt;<ce:hsp sp="0.10"/>900<ce:hsp sp="0.25"/>m2/g), large pore volumes (&gt;<ce:hsp sp="0.10"/>0.9<ce:hsp sp="0.25"/>cm3/g), a tunable pore size (~<ce:hsp sp="0.10"/>1–30<ce:hsp sp="0.25"/>nm), and good chemical and thermal stability; all of which contribute to their suitability for controlled drug release applications. Additionally important, efficient cellular uptake of mesoporous silica particles is size-dependent, with optimal uptake occurring at the sub-micron scale with potential for controlled DNA release <ce:cross-ref refid="bb0025" id="cf0120">[5]</ce:cross-ref>.</ce:para><ce:para id="p0015" view="all">Non-viral spinal gene therapy to suppress neuropathic pain is a relatively new approach that has resulted in successful therapeutic outcomes in a variety of animal models of pathological pain produced by peripheral nerve inflammation and/or trauma from systemic cancer chemotherapeutic administration, peri-sciatic immune activators, or chronic constriction injury <ce:cross-refs refid="bb0060 bb0065 bb0070 bb0075 bb0080" id="cf0125">[12–16]</ce:cross-refs>. However, high transgene doses and limited cargo loading efficiency of polymer platforms were observed, which may minimize the clinical utility of this delivery method. One approach to circumvent these limitations is to deliver therapeutic genes utilizing MSNs for transgene delivery due to their flexibility in cargo loading and release.</ce:para><ce:para id="p0020" view="all">In the present work, <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> long-duration biocompatibility, biodistribution, and functional gene expression following delivery to the spinal cord was conducted using cationic amine-chemically-modified (functionalized) mesoporous silica cores with ~<ce:hsp sp="0.10"/>2<ce:hsp sp="0.25"/>nm diameter pores prepared by aerosol-assisted self-assembly, with phospholipid bilayers fused to the core surface. The term ‘protocell’ will be used to reference MSN-supported lipid bilayers to maintain consistency of nomenclature with the initial published description of their manufacture and characterization <ce:cross-refs refid="bb0045 bb0085 bb0090" id="cf0130">[9,17,18]</ce:cross-refs>. The principle attractiveness of utilizing these protocells as drug and gene delivery platforms is in their potential for increased drug containment properties, and the tenability of surface chemistry modifications tailored to specific cargos.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0025">Materials and methods</ce:section-title><ce:section id="s0015" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0030">Animals</ce:section-title><ce:para id="p0025" view="all">A total of 62 adult, male Sprague–Dawley rats (Harlan Labs, Houston, TX); 300<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>5<ce:hsp sp="0.25"/>g were double housed at 21<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>4<ce:hsp sp="0.25"/>°C in light controlled rooms (12:12 light:dark) and fed standard rodent chow and water available <ce:italic>ad libitum</ce:italic>. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of New Mexico, and conducted in accordance to the guidelines recommended by the International Association for the Study of Pain for the handling and use of laboratory animals.</ce:para></ce:section><ce:section id="s0020" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0035">Behavioral assessment for sensory changes</ce:section-title><ce:para id="p0030" view="all">Baseline spinal cord activity is evaluated using the well-characterized protocol for assessing threshold responses to light touch applied to the hindpaws with a series of calibrated monofilaments (0.4–15<ce:hsp sp="0.25"/>g). The monofilaments generate a touch stimulus when applied to the hindpaw that induces a paw withdrawal response within 8<ce:hsp sp="0.25"/>s <ce:cross-refs refid="bb0095 bb0100" id="cf0135">[19,20]</ce:cross-refs>. Paw withdrawal sensory thresholds are highly sensitive to subtle inflammatory perturbations in the spinal cord, as normal hindpaw response thresholds (5–10<ce:hsp sp="0.25"/>g) are present during healthy, non-pathological conditions <ce:cross-refs refid="bb0100 bb0105" id="cf0140">[20,21]</ce:cross-refs> while response thresholds dramatically decrease (&lt;<ce:hsp sp="0.10"/>1<ce:hsp sp="0.25"/>g) in the presence of inflammatory signaling <ce:cross-refs refid="bb0100 bb0105" id="cf0145">[20,21]</ce:cross-refs>. This behavioral response phenotype is used as an indicator of spinal cord health. Prior to behavioral thresholds, rats were habituated to the testing conditions for 4 consecutive days, 1<ce:hsp sp="0.25"/>h/day, in a quiet dimly lit and temperature controlled room (26.0–27.0<ce:hsp sp="0.25"/>°C), where rats were placed on top of an open grid of bars with 2<ce:hsp sp="0.25"/>mm thickness, spaced 8<ce:hsp sp="0.25"/>mm apart to allow access to the entire plantar surface of the hindpaw for tactile stimulation. Response thresholds were determined by a logarithmic series of calibrated Semmes-Weinstein monofilaments (von Frey hairs; Stoeling, Wood Dale, IL). Testing of behavioral thresholds were conducted identically to that described previously <ce:cross-refs refid="bb0100 bb0105" id="cf0150">[20,21]</ce:cross-refs>. Briefly, baseline (BL) responses to light mechanical touch stimuli were assessed using 10 monofilaments, each with a log-stiffness value, defined as log10 (milligrams ×<ce:hsp sp="0.10"/>10), values in grams follow in parentheses: 3.61 (.407), 3.84 (.692), 4.08 (1.202), 4.17 (1.48), 4.31 (2.04), 4.56 (3.63), 4.74 (5.49), 4.93 (8.51), 5.07 (11.75) and 5.18 (15.14). BL values derived from three threshold assessments, at 20<ce:hsp sp="0.25"/>min intervals, were averaged for the right and left hindpaws separately. After injection of protocells, threshold responses were re-assessed at .5, 1, 2, 3, 24 and 72<ce:hsp sp="0.25"/>h. In those rats that underwent unilateral sciatic nerve injury, thresholds were reassessed at 3 and 10<ce:hsp sp="0.25"/>days post-surgery and every 2<ce:hsp sp="0.25"/>days, up to 32<ce:hsp sp="0.25"/>days post-peri-spinal (intrathecal; i.t.) protocell injection. To assess normal food consumption as an indication of general health, body weights were measured following 2, 4, 8, 12, 14, 21, 28, and 56<ce:hsp sp="0.25"/>days following i.t. administration of protocells.</ce:para></ce:section><ce:section id="s0025" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0040">Chronic constriction injury (CCI)</ce:section-title><ce:para id="p0035" view="all">The surgical procedure for chronic constriction injury (CCI) was performed identically as previously described <ce:cross-ref refid="bb0110" id="cf0155">[22]</ce:cross-ref>. Briefly, under isofluorane anesthesia (1.5–2.0<ce:hsp sp="0.25"/>vol.% in oxygen), the mid to lower back and dorsal thigh were shaved and cleaned with diluted Bacti-Stat AE (EcoLab HealthCare Division, Mississauga, Ontario, Canada). Using aseptic procedures, the sciatic nerve was carefully isolated and four chromic gut sutures (Ethicon, Somerville, NJ) were loosely tied around one sciatic nerve. The overlying muscle was sutured closed with two, sterile, silk sutures (Ethicon, Somerville, NJ), and the overlying skin was closed with wound clips. The sciatic nerve of sham-operated rats were identically exposed but not ligated. Animal body weight was recorded and recovery from anesthesia was observed within 10<ce:hsp sp="0.25"/>min.</ce:para></ce:section><ce:section id="s0030" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0045">Intrathecal (i.t.) injections</ce:section-title><ce:para id="p0040" view="all">Injections were acutely administered and conducted as described previously <ce:cross-refs refid="bb0070 bb0115" id="cf0160">[14,23]</ce:cross-refs>. Briefly, rats were anesthetized with isofluorane (5.0<ce:hsp sp="0.25"/>vol.% in oxygen) and an 18-gauge cannula constructed from an 18-gauge sterile hypodermic needle (Becton Dickinson &amp; Co., Franklin Lakes, NJ) removed from its hub was inserted percutaneously between lumbar vertebrae 5 and 6 (L5–6). During this time, a small amount of cerebral spinal fluid (CSF) efflux from the 18-gauge cannula and a tail flick were observed, indicating subarachnoid catheter placement. A 1<ce:hsp sp="0.25"/>ml Hamilton syringe connected to a 30-gauge, 0.5<ce:hsp sp="0.25"/>inch needle inserted into a catheter composed of a 30<ce:hsp sp="0.25"/>cm-length polyethylene tubing (PE-10; cat# 427401; Becton Dickinson, Sparks, MD) was then used to draw up DOTAP:Chol or DOPC protocells (1.0, 0.1 or 0.01<ce:hsp sp="0.25"/>mg) in a total volume of 20<ce:hsp sp="0.25"/>μl sterile, isotonic saline. The drug-filled PE-10 catheter was then inserted into the open end of the 18-gauge guide cannula and advanced 7.7<ce:hsp sp="0.25"/>mm rostrally, placing the internal portion of the PE-10 catheter at the lumbosacral enlargement of the spinal cord where axon terminals of sciatic afferent nerve fibers synapse onto pain-relevant spinal cord neurons. Injections were given over a 0.5–1<ce:hsp sp="0.25"/>minute interval. Following drug injection, the PE-10 catheter was removed followed by removal of the 18-gauge cannula, and both were discarded. The total time required for these i.t. injections was 2–3<ce:hsp sp="0.25"/>min. All animals displayed full motor activity following recovery from anesthesia.</ce:para></ce:section><ce:section id="s0035" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0050">Preparation of plasmid DNA</ce:section-title><ce:para id="p0045" view="all">The plasmid vector used in these studies was identical to that previously described <ce:cross-ref refid="bb0115" id="cf0165">[23]</ce:cross-ref>. This plasmid's transcriptional cassette consists of a cytomegalovirus (CMV) enhancer/chicken beta-actin (CB) promoter driving the expression of rat IL-10 gene containing a point mutation (F129S) and the SV40 polyadenylation signal. The identical plasmid lacking the IL-10 gene was used as a control (control DNA). Both plasmids were amplified in SURE II competent <ce:italic>Escherichia coli</ce:italic> (Stratagene, Cedar Creek, TX) and isolated using an endotoxin free Giga plasmid purification kit (Qiagen, Valencia, CA).</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0055">Preparation of mesoporous cationic silica “core” protocells</ce:section-title><ce:para id="p0050" view="all">The mesoporous silica particles were prepared by the surfactant self-assembly method described previously <ce:cross-refs refid="bb0090 bb0120" id="cf0170">[18,24]</ce:cross-refs>. Briefly, a homogeneous solution of the soluble silica precursor, tetraethylorthosilicate (TEOS; Sigma-Aldrich Corp., St. Louis, MO), and hydrochloric acid was mixed in ethanol and water. A surfactant, cetyltrimethylammonium bromide (CTAB; Sigma-Aldrich Corp., St. Louis, MO), with an initial concentration much less than the critical micelle concentration was added to lower the surface tension of the liquid mixture and act as the mesoporous structure-directing template. Aerosol solutions of soluble silica plus surfactant were then generated with nitrogen as a carrier atomizing gas using a commercially available atomizer (Model 9392A, TSI, Inc., St. Paul, MN). The aerosol droplets were solidified in a tube furnace at 400<ce:hsp sp="0.25"/>°C until dry. Once dried, a durapore membrane filter, kept at 80<ce:hsp sp="0.25"/>°C, was used to collect the particles. As a final step, the surfactant was removed at 400<ce:hsp sp="0.25"/>°C for 5<ce:hsp sp="0.25"/>h <ce:italic>via</ce:italic> calcination. The surface of the mesoporous silica core in these studies was chemically modified with 10<ce:hsp sp="0.25"/>wt.% or 15<ce:hsp sp="0.25"/>wt.% by aminopropyltriethoxysilane (APTES; Sigma-Aldrich Corp., St. Louis, MO) conducted identically as previously described <ce:cross-ref refid="bb0085" id="cf0175">[17]</ce:cross-ref> to create a positive surface charge to increase loading efficiency of negatively charged cargo. Further, Liu and colleagues report the colloidal stability of these protocells with lipid bilayers, excess amount of liposomes (50<ce:hsp sp="0.25"/>μg liposomes per 0.5<ce:hsp sp="0.25"/>mg silica were used <ce:cross-ref refid="bb0090" id="cf0180">[18]</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0060">Preparation of liposome-supported bilayers (protocells)</ce:section-title><ce:para id="p0055" view="all">The lipids used in this study were either positively charged, 1, 2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP; cat. # 890890C; Avanti Polar Lipids Inc., Alabaster, AL) or zwitterionic and neutrally charged, 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; cat. # 850375; Avanti Polar Lipids Inc., Alabaster, AL). Cholesterol (Sigma-Aldrich) was added to DOTAP in a 1:1 ratio (25<ce:hsp sp="0.25"/>mg each), as it has been reported to improve transfection efficiency when included in cationic liposomes <ce:cross-ref refid="bb0125" id="cf0185">[25]</ce:cross-ref>. DOTAP:Chol was dissolved in chloroform, followed by evaporation under nitrogen flow. Phospholipids were dissolved in chloroform at concentrations of 10–25<ce:hsp sp="0.25"/>mg/ml. Lipid aliquots of 2.5<ce:hsp sp="0.25"/>mg were placed in scintillation vials. In some experiments where lipids were examined under confocal microscopy, Alexa Fluor 647, a red fluorescent dye (absorption 650<ce:hsp sp="0.25"/>nm and emission 658<ce:hsp sp="0.25"/>nm; Invitrogen, Carlsbad, CA), was added at 2% for these labeling and biodistribution studies. Chloroform was then evaporated under nitrogen flow. The vials were then stored overnight in a vacuum oven to remove remaining chloroform. Samples were stored at −<ce:hsp sp="0.10"/>20<ce:hsp sp="0.25"/>°C until used.</ce:para><ce:para id="p0060" view="all">To prepare liposomes, vials were brought to room temperature and samples were rehydrated with 1<ce:hsp sp="0.25"/>ml buffer (10<ce:hsp sp="0.25"/>mM MOPS, pH<ce:hsp sp="0.25"/>7.0, 60<ce:hsp sp="0.25"/>mM NaCl) and shaken for 1<ce:hsp sp="0.25"/>h, which resulted in a cloudy suspension. The suspension was extruded through a 100<ce:hsp sp="0.25"/>nm pore diameter membrane with in a mini-extruder (Avanti Polar Lipids), and repeated for a minimum of 21 times. The resulting liquid was placed in a fresh vial and stored at 4<ce:hsp sp="0.25"/>°C until used in the preparation of DNA loaded protocells.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0065">Preparation of DNA (either 18-bp or pDNA) loaded “protocells”</ce:section-title><ce:para id="p0065" view="all">An 18<ce:hsp sp="0.25"/>bp-DNA oligomer (5′-CTTGAGAAAGGGCTGCCA-3′) tagged with 6-carboxylfluorocein (FAM, emission 520<ce:hsp sp="0.25"/>nm, or fluorescein isothiocyanate, FITC emission 488<ce:hsp sp="0.25"/>nm; Invitrogen, Carlsbad, CA) was used to identify the safety profile and anatomical location of protocell cargo following i.t. injection. To load the silica core with pDNA <ce:italic>in vivo</ce:italic> behavioral experiments, 35<ce:hsp sp="0.25"/>μl of 200<ce:hsp sp="0.25"/>μM DNA was added to 3.5<ce:hsp sp="0.25"/>mg of cationic silica nanoparticles, gently mixed in sterile 0.5<ce:hsp sp="0.10"/>× PBS (25<ce:hsp sp="0.25"/>mg/ml; 140<ce:hsp sp="0.25"/>μl per 3.5<ce:hsp sp="0.25"/>mg particles) and allowed to incubate for 5<ce:hsp sp="0.25"/>min. In a sterile microcentrifuge tube, 300<ce:hsp sp="0.25"/>μl of 2.5<ce:hsp sp="0.25"/>mg/ml of liposome mixture was added and mixed with the nanoparticle/DNA mixture by pipetting until homogeneous. The resulting mixture was allowed to sit at room temperature for 1<ce:hsp sp="0.25"/>h with occasional agitation by pipetting and then centrifuged for 2<ce:hsp sp="0.25"/>min. at 6000<ce:hsp sp="0.25"/>RPM to remove excess lipids. The supernatant was discarded, and the pellet was washed in sterile PBS followed by centrifugation at 6000<ce:hsp sp="0.25"/>RPM. Pellets (protocell/18mer-DNA-FAM/lipid mixture) were washed 3<ce:hsp sp="0.10"/>× and resuspended in sterile PBS at 50, 5 or 0.5<ce:hsp sp="0.25"/>mg/ml. For pDNA loading onto protocells in cell culture experiments, identical steps were followed with DOTAP:Chol lipids resuspended with PBS (pH<ce:hsp sp="0.25"/>7.4) containing 5<ce:hsp sp="0.25"/>μg rat pDNA-IL-10. Following resuspension with PBS (pH<ce:hsp sp="0.25"/>7.4), liposome size and zeta potential were characterized by dynamic light scattering using a Zetatrac Ultra151 dynamic light scattering (DLS) instrument (Microtrac Inc., Montgomeryville, PA) and Microtrac FLEX 10.6.1 analysis software. Measurements were made in triplicate using a standard filter with high resolution, high sensitivity and a scan time of 240<ce:hsp sp="0.25"/>s. For <ce:italic>in vivo</ce:italic> behavioral assessment of protocell-delivered IL-10 gene therapy, identical steps described above were followed with DOTAP:Chol lipids resuspended in 50<ce:hsp sp="0.25"/>mg/ml to yield a final dose and concentration of 10<ce:hsp sp="0.25"/>μg pDNA/mg protocell/20<ce:hsp sp="0.25"/>μl PBS.</ce:para></ce:section><ce:section id="s0055" view="all"><ce:label>2.9</ce:label><ce:section-title id="st0070">Characterization of mesoporous silica particles</ce:section-title><ce:para id="p0070" view="all">Transmission electron microscopy (TEM) images were acquired with a JEOL 2010 200<ce:hsp sp="0.25"/>kV high-resolution transmission electron microscope. The pore diameter was calculated by the Barret–Joyner–Halenda (BJH) method <ce:cross-ref refid="bb0130" id="cf0190">[26]</ce:cross-ref>. Particle size distribution of 15<ce:hsp sp="0.25"/>mol% APTES modified mesoporous silica cores as measured by dynamic light scattering. The nitrogen sorption isotherm of the silica particles exhibit a Type IV nitrogen adsorption–desorption isotherms, as previously characterized <ce:cross-ref refid="bb0135" id="cf0195">[27]</ce:cross-ref>. Using the Barrett–Joyner–Halenda (BJH) model, the pore diameter was determined revealing a narrow distribution. The total surface area was calculated by the Brunauer, Emmett &amp; Teller (BET) method <ce:cross-ref refid="bb0140" id="cf0200">[28]</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0060" view="all"><ce:label>2.10</ce:label><ce:section-title id="st0075">Characterization of cargo release-rate from protocells</ce:section-title><ce:para id="p0075" view="all">Mesoporous silica nanoparticles (25<ce:hsp sp="0.25"/>mg) modified with 15% APTES and supporting either a surface coating of DOTAP:Chol 1:1 (DOTAP:Chol) or DOPC lipid bilayer, were dispersed in 1<ce:hsp sp="0.25"/>ml PBS to give a concentration of 25<ce:hsp sp="0.25"/>mg/ml 12.5<ce:hsp sp="0.25"/>μl of 20<ce:hsp sp="0.25"/>mM dextran–tetramethylrhodamine (DexRho; 10,000<ce:hsp sp="0.25"/>MW, Anionic, Molecular Probes, Invitrogen, Carlsbad, CA, cat# D-1868) to yield ~<ce:hsp sp="0.10"/>250<ce:hsp sp="0.25"/>μM. The solution was agitated at room temperature for 45<ce:hsp sp="0.25"/>min, and 50<ce:hsp sp="0.25"/>μl aliquots of each protocell formulation for each timepoint were centrifuged for 2<ce:hsp sp="0.25"/>min, washed 3<ce:hsp sp="0.10"/>× with 200<ce:hsp sp="0.25"/>μl of 0.25<ce:hsp sp="0.10"/>× PBS to remove unincorporated dye and excess lipids. A total of 200<ce:hsp sp="0.25"/>μl of pH appropriate buffer was added to each sample (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3) to give a final concentration of 6.25<ce:hsp sp="0.25"/>μg/μl. The particles and buffers were kept at 37<ce:hsp sp="0.25"/>°C. At designated timepoints, 1, 3, 6, 24, 48, 72, 96 and 168<ce:hsp sp="0.25"/>h (1<ce:hsp sp="0.25"/>week), samples were removed, centrifuged at 14,000<ce:hsp sp="0.25"/>RPM for 2<ce:hsp sp="0.25"/>min to precipitate the silica. A 100<ce:hsp sp="0.25"/>μl sample of supernatant was then transferred into a borosilicate microcuvette to measure absorbance at 555<ce:hsp sp="0.25"/>nm on a Beckman DU 530 UV/vis spectrophotometer (Beckman-Coulter, Inc., Fullerton, CA). In order to determine the quantity of dye released, absorbance readings from the supernatant samples were compared against a set of standards from a serial dilution curve based on known concentrations of dextran–tetramethylrhodamine. The following buffers were brought to a 1<ce:hsp sp="0.25"/>l volume in dH20 to generate the corresponding pH values: 0.1<ce:hsp sp="0.25"/>M acetic acid (pH<ce:hsp sp="0.25"/>2), 0.1<ce:hsp sp="0.25"/>M citrate with 0.03% H2O2 (pH<ce:hsp sp="0.25"/>4), 10.0<ce:hsp sp="0.25"/>mM PBS (pH<ce:hsp sp="0.25"/>7.4), 10.0<ce:hsp sp="0.25"/>mM PBS with 0.1% BSA (pH<ce:hsp sp="0.25"/>8.0), and 0.1<ce:hsp sp="0.25"/>M Amino-Methyl-Propanediol (pH<ce:hsp sp="0.25"/>10).</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>2.11</ce:label><ce:section-title id="st0080">Examination of tissue samples by fluorescence microscopy</ce:section-title><ce:para id="p0080" view="all">For tissue collection, rats were euthanized by overdosing with sodium pentobarbital (Abbott Laboratories, North Chicago, IL) at 72<ce:hsp sp="0.25"/>h, and 2, 4 and 8<ce:hsp sp="0.25"/>weeks (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 rats for each timepoint and each protocell formulation; DOTAP:Chol or DOPC). Blood samples were taken and mixed with 0.1<ce:hsp sp="0.25"/>ml heparin (APP Pharmaceuticals, LLC, Schaumburg, IL) to prevent clotting. Transcardial PBS (warmed to ~<ce:hsp sp="0.10"/>45<ce:hsp sp="0.25"/>°C; 3–5<ce:hsp sp="0.25"/>min) perfusion was followed by room temperature .01<ce:hsp sp="0.25"/>M PBS; (3–5<ce:hsp sp="0.25"/>min), and then ice cold 4% paraformaldehyde (pH<ce:hsp sp="0.25"/>7.24; 6–8<ce:hsp sp="0.25"/>min) perfusion. Spinal cord, brain, cervical nodes, thymus, spleen, kidney and liver were harvested and post-fixed in 4% paraformaldehyde overnight and transferred to PBS and stored at 4<ce:hsp sp="0.25"/>°C. Bone encased spinal cords were placed in 10% ethylenediaminetetraacetic acid (EDTA) solution (~<ce:hsp sp="0.10"/>3–4<ce:hsp sp="0.25"/>weeks) to chelate calcium and soften bone for sectioning spinal cord encased in the spinal column to maintain anatomical integrity of the perispinal meninges. The entire spinal cord was cut and cross-sectioned into five, 5<ce:hsp sp="0.25"/>mm, segments starting at the i.t. injection site (pt 0) and proceeding both rostrally and caudally. Brain and organ tissues were cryoprotected in 30% sucrose in (0.1<ce:hsp sp="0.25"/>M PBS<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>50<ce:hsp sp="0.25"/>μl 10% sodium azide) for 24<ce:hsp sp="0.25"/>h, embedded in O.C.T. compound in cryomolds (cat# 4565-Sakura Finetek, Torrance, CA), flash frozen in 45<ce:hsp sp="0.25"/>°C isopentane on dry ice and finally stored at −<ce:hsp sp="0.10"/>80<ce:hsp sp="0.25"/>°C until the time of sectioning. For cryosectioning, 10<ce:hsp sp="0.25"/>μm tissue slices were cut on a cryotome, Microm HM 505E (Zeiss, Thornwood, NY), and placed on Vectabond (Vector Laboratories, Burlingame, CA) coated slides.</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>2.12</ce:label><ce:section-title id="st0085">Quantitative spectral imaging</ce:section-title><ce:para id="p0085" view="all">For FAM-tagged DNA, multi-spectral tissue imaging and quantification were conducted as previously described <ce:cross-ref refid="bb0145" id="cf0205">[29]</ce:cross-ref>. Briefly, images were obtained using an Axioscope microscope connected to a Nuance Camera 2.8 (FX) Multispectral Imaging System (Cambridge Research and Instrumentation Inc., (CRI) Woburn, MA) <ce:cross-ref refid="bb0145" id="cf0210">[29]</ce:cross-ref>. This camera contains a liquid crystal tunable filter (LCTF) capable of filtering light from 400 to 720<ce:hsp sp="0.25"/>nm, and can capture a series of images of a particular tissue region at 10<ce:hsp sp="0.25"/>nm wavelength increments. Every pixel of every image (series collected at specific 10<ce:hsp sp="0.25"/>nm wavelength increment) was then analyzed by CRI software to determine its peak spectral intensities from 400 to 720<ce:hsp sp="0.25"/>nm. For each tissue type examined, the software subtracts background autofluorescence, defined as any spectral emission falling outside the 10<ce:hsp sp="0.25"/>nm wavelength range used for analysis. True FAM signal (excitation 494<ce:hsp sp="0.25"/>nm, emission 522<ce:hsp sp="0.25"/>nm) was determined from a control cover-slipped slide on which a small drop of 100<ce:hsp sp="0.10"/>× diluted FAM-tagged DNA 18-oligomer was placed. The autofluorescence was determined by imaging naïve tissue. The intensity of FAM fluorescence across the full wavelength range (400–720) was calculated using the Nuance computer software. A minimum threshold intensity was set automatically by the software and FAM spectral emissions below this point were not included in the calculation. The FAM intensity signal “counts” were then averaged per exposure time (sec) per mm<ce:sup loc="post">2</ce:sup> area for each image collected (signal counts/s/mm<ce:sup loc="post">2</ce:sup>). An image was acquired for each of 4 slices (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>4) per tissue region (<ce:italic>e.g.</ce:italic> spinal cord) per rat, and then averaged to generate a mean value for a tissue region per rat (N<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 rats/treatment group). An overall mean value is calculated for each treatment group, and the data are reported as signal counts/s/mm<ce:sup loc="post">2</ce:sup>. Detailed information regarding the computer software can be found on the Caliper Life Science website, a subsidiary of Perkin-Elmer (URL: <ce:inter-ref xlink:href="http://www.caliperls.com/products/microscopy-imaging-analysis/microscopy-imaging/nuance-fx.htm" id="ir0025" xlink:type="simple">http://www.caliperls.com/products/microscopy-imaging-analysis/microscopy-imaging/nuance-fx.htm</ce:inter-ref>).</ce:para></ce:section><ce:section id="s0075" view="all"><ce:label>2.13</ce:label><ce:section-title id="st0090">Immunohistochemistry</ce:section-title><ce:para id="p0090" view="all">Tissues were collected and sliced identically as described above (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 rats with 12 slices per anatomical area). Tissues were permeabilized with 0.5%Triton-X and blocked against non-specific antibody binding in PBS<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>5% BSA<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>0.5% Triton-X for 1<ce:hsp sp="0.25"/>h at RT. Primary antibodies were diluted in a solution of PBS with 0.1% BSA, 0.3% Triton-X with 0.1% sodium azide and incubated overnight at RT in a humidity chamber with slight rotation. Primary antibodies were diluted as follows: ED1/CD68 (1:300; a marker for macrophage activity, ED1-cat# SC-7084, Santa Cruz Biotechnology, Santa Cruz, CA); GFAP (1:300, astroglia; cat# AB5804, Millipore, Temecula, CA), Cd11b (microglia/macrophage, 1:300, monoclonal OX42, cat# MCA 275EL, AbD Serotec, Raleigh, NC), and Cleaved-Caspase 3 (Asp175) (apoptotic cells, 1:200, cat#9664 Cell Signaling Technology, Beverly, MA). Slices were washed 3<ce:hsp sp="0.10"/>× with 0.1<ce:hsp sp="0.25"/>M PBS and then incubated for 2<ce:hsp sp="0.25"/>h at room temperature in a dimly lit room at a 1:200 dilution of a Rhodamine Red-labeled secondary antibody (Jackson Immunoresearch Laboratories, West Grove, PA) in the same solution as that used for primary antibodies. Unbound secondary antibody was removed by 3<ce:hsp sp="0.10"/>× washes (5<ce:hsp sp="0.25"/>min each in 0.1<ce:hsp sp="0.25"/>M PBS). Slices were then covered with the fluoro-protectant, Vectashield, containing the nuclear stain DAPI (4, 6-diamidino-2-phenylindole) (Vector Laboratories, Burlingame, CA), cover slipped, and stored at 4<ce:hsp sp="0.25"/>°C. Three slides, with 3 tissue sections on each slide (n<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>9), were examined for each primary antibody. As a negative control, no primary antibody was added to an additional slide. A positive control for the Caspase-3 antibody was also included in this experiment. Cultures of Raw 264.7 mouse macrophage cells, a cell type similar to that present in CNS meninges, were treated with bacterial lipopolysaccharide (LPS; 1<ce:hsp sp="0.25"/>μg/ml) for 2<ce:hsp sp="0.25"/>h to initiate apoptosis, and then were subjected to the activated Caspase-3 antibody. Red apoptotic cells stained positively and confirmed the integrity of the Caspase-3 antibody (data not shown). Tissues or cells were examined using an Olympus BX-60 fluorescent microscope, Olympus D71 camera and software (Olympus America, Inc., Center Valley, PA).</ce:para></ce:section><ce:section id="s0080" view="all"><ce:label>2.14</ce:label><ce:section-title id="st0095">Confocal imaging</ce:section-title><ce:para id="p0095" view="all">To determine subcellular location of FAM-tagged 18<ce:hsp sp="0.25"/>bp DNA loaded onto protocells, or FITC-tagged 18<ce:hsp sp="0.25"/>bp DNA loaded onto liposome-tagged Alexa Fluor 647, 40<ce:hsp sp="0.10"/>× or 20<ce:hsp sp="0.10"/>× confocal image z-stacks were obtained with a Zeiss Axiovert 100 inverted microscope (Carl Zeiss Laser Optics, Oberkochen, Germany) using LSM510 Image Acquisition software. The microscope excited the fluorophore of interest DAPI, FAM, FITC, Rhodamine, or Alexa Fluor 647 with one of three lasers: argon—405<ce:hsp sp="0.25"/>nm; NeHe1—543<ce:hsp sp="0.25"/>nm; and HeNe2—633<ce:hsp sp="0.25"/>nm respectively.</ce:para></ce:section><ce:section id="s0085" view="all"><ce:label>2.15</ce:label><ce:section-title id="st0100">Cellular transfection</ce:section-title><ce:para id="p0100" view="all">For human embryonic kidney cell (HEK 293) cultures, cells were purchased from American Type Culture Collection (ATCC; Manassas, VA-cat# CRL-1573), and maintained in Minimum Essential Medium containing Earle's Salts and l-glutamine (Invitrogen, cat# 11095) to which was added 10% heat inactivated fetal calf serum (FCS) (Gibco, cat#10438) and 100<ce:hsp sp="0.25"/>U/ml penicillin and 100<ce:hsp sp="0.25"/>μg/ml Streptomycin (Gibco, cat# 15400). Cells were allowed to grow to 80% confluence and were then trypsinized with 0.05% Trypsin-EDTA (Gibco-cat# 15400) to loosen cells. The cell suspension was centrifuged in a sterile 50<ce:hsp sp="0.25"/>ml conical tube at 1500<ce:hsp sp="0.25"/>RPM for 5<ce:hsp sp="0.25"/>min at 4<ce:hsp sp="0.25"/>°C. After adding 20<ce:hsp sp="0.25"/>ml of fresh media, the cells were counted by standard technique on a hemocytometer and passed to a new sterile T-75 flask, plated at 10.0–15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>106 at each pass. Cells were incubated at 37<ce:hsp sp="0.25"/>°C with an atmosphere of air, 95% and CO2, 5% until experimental procedures.</ce:para><ce:para id="p0105" view="all">For transfection with protocells, HEK 293 cells were plated at 1.0<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup><ce:hsp sp="0.25"/>cells/ml on 24 well sterile poly-<ce:small-caps>d</ce:small-caps> lysine coated culture plates (Becton Dickinson, Twin Oak Park, Bedford, MA) in 1<ce:hsp sp="0.25"/>ml sterile MEM or DMEM respectively, both supplemented with 10% heat inactivated FCS and 100<ce:hsp sp="0.25"/>U/ml penicillin and 100<ce:hsp sp="0.25"/>μg/ml streptomycin and allowed to grow 24<ce:hsp sp="0.25"/>h to 80% confluence. Media was exchanged with 1<ce:hsp sp="0.25"/>ml fresh media containing 500, 50, 25, 10, and .5<ce:hsp sp="0.25"/>μg/ml DOTAP or DOPC protocells loaded with pDNA-IL-10-GFP (5, 0.5, 0.25, 0.1 or 0.05<ce:hsp sp="0.25"/>μg/ml), pDNA-IL-10 (5, 0.5, 0.25, 0.1 or 0.05<ce:hsp sp="0.25"/>μg/ml). In a separate experiment, media was exchanged with 1<ce:hsp sp="0.25"/>ml fresh media containing LPS (10<ce:hsp sp="0.25"/>ng), naked pDNA-IL-10 (5<ce:hsp sp="0.25"/>μg), or DOTAP:Chol<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>pDNA-IL-10 (5<ce:hsp sp="0.25"/>μg) lacking the mesoporous silica core. The protocell containing media was removed after 5<ce:hsp sp="0.25"/>h and replaced with fresh media. Media was collected 24<ce:hsp sp="0.25"/>h later and analyzed for GFP transfection (green fluorescence) and/or IL-10 protein release using rat IL-10 specific Quantikine™ ELISA kit (R&amp;D Systems, Minneapolis, MN) according to manufacturer's instructions, or immunostaining with IL-10 primary antibody (R&amp;D Systems, Minneapolis, MN) with Rhodamine 2° antibody in a procedure identical to that used for the immunohistochemical staining outlined above.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:label>2.16</ce:label><ce:section-title id="st0105">Cell viability assay</ce:section-title><ce:para id="p0110" view="all">HEK 293 cells were plated at 5–6<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup><ce:hsp sp="0.25"/>cells/ml on 24-well sterile poly-<ce:small-caps>d</ce:small-caps> lysine coated culture plates (Becton Dickinson, Twin Oak Park, Bedford, MA) in 1<ce:hsp sp="0.25"/>ml sterile MEM supplemented with 10% heat inactivated FCS, 100<ce:hsp sp="0.25"/>U/ml penicillin and 100<ce:hsp sp="0.25"/>μg/ml streptomycin, and allowed to grow to 80% confluence. Media was removed and 1<ce:hsp sp="0.25"/>ml of fresh media was added containing 500, 50, 25, 10, and .5<ce:hsp sp="0.25"/>μg/ml DOTAP or DOPC protocells loaded with pDNA-IL-10-GFP, or blank protocells. The media was removed after 5<ce:hsp sp="0.25"/>h and replaced with fresh media and the cells were allowed to incubate for an additional 21<ce:hsp sp="0.25"/>h. Cells were removed with a standard sterile cell scraper and 500<ce:hsp sp="0.25"/>μl of cell suspensions placed in a flow cytometry tube on ice (Falcon cat# 352008—Becton Dickinson Labware, Franklin Lakes, NJ). Saponin (0.1%) was used to induce cell death for assay to compare against other experimental manipulations. 3<ce:hsp sp="0.25"/>min before examination by flow cytometry (Facscan4, Becton Dickinson), 50<ce:hsp sp="0.25"/>μl of 10<ce:hsp sp="0.25"/>μM ethidium-homodimer D-1 was added to label dead cells.</ce:para></ce:section><ce:section id="s0095" view="all"><ce:label>2.17</ce:label><ce:section-title id="st0110">Mouse macrophage (Raw 264.7) cells for nitric oxide assay</ce:section-title><ce:para id="p0115" view="all">Raw 264.7 cells were obtained from American Type Culture Collection (ATCC, Manassas VA, USA—cat# TIB-71) and cultured as adherent cells in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, cat# D6429) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, cat# 10082-147) and 100<ce:hsp sp="0.25"/>U/ml penicillin and 100<ce:hsp sp="0.25"/>μg/ml streptomycin (Gibco—cat#-15140122) and maintained at 37<ce:hsp sp="0.25"/>°C under humidified 5% CO2 atmosphere. Cells were grown to 85% confluency, collected by scraping, and sub-cultured for 3 passages. For these experiments, dead cells were counted by hemocytometer using trypan blue exclusion.</ce:para><ce:section id="s0100" view="all"><ce:label>2.17.1</ce:label><ce:section-title id="st0115">Measurement of nitric oxide production</ce:section-title><ce:para id="p0120" view="all">Raw 264.7 cells were seeded at a density of 2.75<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">5</ce:sup><ce:hsp sp="0.25"/>cells/ml in 24 well plates 24<ce:hsp sp="0.25"/>h prior to experimentation and maintained at 37<ce:hsp sp="0.25"/>°C under humidified 5% CO2 atmosphere. At 85% confluency, the supernatant was exchanged with DMEM containing different formulations of DMEM and protocells or protocell constituents and followed by a 2<ce:hsp sp="0.25"/>h incubation then washed twice in PBS (pH<ce:hsp sp="0.25"/>7.4, Gibco—cat# 10010). Wells treated with 10<ce:hsp sp="0.25"/>ng/ml lipopolysaccharides from <ce:italic>E. coli</ce:italic> (LPS, Sigma-Aldrich, cat# L6529) were exposed to DMEM containing LPS for 10<ce:hsp sp="0.25"/>min followed by removal and washed twice in PBS. Nitric oxide production was measured using the commercially available Griess Reagent System (Promega, USA, cat#-G2930) according to the manufacturer's instructions. Absorbance was measured at 550<ce:hsp sp="0.25"/>nm using a Tecan Infinite® plate reader (Tecan Systems, Inc., San Jose, CA). All experiments were run in triplicate.</ce:para></ce:section></ce:section><ce:section id="s0105" view="all"><ce:label>2.18</ce:label><ce:section-title id="st0120">Data analysis</ce:section-title><ce:para id="p0125" view="all">Psychometric behavioral analysis was performed as previously described <ce:cross-ref refid="bb0100" id="cf0215">[20]</ce:cross-ref> to compute the absolute threshold that resulted in the 50% hindpaw withdrawal response. As described previously <ce:cross-refs refid="bb0100 bb0105 bb0150" id="cf0220">[20,21,30]</ce:cross-refs> withdrawal thresholds were determined by using the software program, PsychoFit. The software for PsychoFit may be downloaded from L.O. Harvey's website (<ce:inter-ref xlink:href="http://psych.colorado.edu/~lharvey" id="ir0030" xlink:type="simple">http://psych.colorado.edu/~lharvey</ce:inter-ref>). This program fits the pattern of hindpaw responses for each timepoint to a Gaussian integral psychometric function and generates a 50% threshold value for that timepoint. As such, parametric statistical analyses (repeated measures ANOVA) are applied to determine the statistical significance between treatment groups at multiple timepoints using the computer software, GraphPad Prism, version 4.03 (GraphPad Software Inc., San Diego, CA). All other statistical analyses were performed using the computer software, GraphPad Prism, version 4.03 (GraphPad Software Inc., San Diego, CA). All data is expressed as mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SEM. Post hoc analysis was completed using Bonferroni's test.</ce:para></ce:section></ce:section><ce:section id="s0110" view="all"><ce:label>3</ce:label><ce:section-title id="st0125">Results</ce:section-title><ce:para id="p0130" view="all">Mesoporous silica particle cores were prepared by the surfactant templated aerosol-assisted self-assembly method previously developed and communicated <ce:cross-ref refid="bb0090" id="cf0225">[18]</ce:cross-ref>. The resulting hydrophilic nanoparticles were further modified with APTES and characterized by a uniform, ordered and connected mesoporosity (<ce:cross-ref refid="f0010" id="cf0230">Fig. 1</ce:cross-ref>A<ce:float-anchor refid="f0010"/>), with a positive of 24<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>5<ce:hsp sp="0.25"/>mV in 0.5<ce:hsp sp="0.10"/>× PBS, or when fused with DOTAP:Chol or neutral DOPC, 4.5<ce:hsp sp="0.25"/>mV<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>2.2<ce:hsp sp="0.25"/>mV or −<ce:hsp sp="0.10"/>11.4<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>3.6<ce:hsp sp="0.25"/>mV, respectively. The average size is ~<ce:hsp sp="0.10"/>230<ce:hsp sp="0.25"/>nm with a specific surface area of 935<ce:hsp sp="0.25"/>m<ce:sup loc="post">2</ce:sup>/g and pore diameter of 2–5<ce:hsp sp="0.25"/>nm (<ce:cross-ref refid="f0010" id="cf0235">Fig. 1</ce:cross-ref>B, D). Cryogenic TEM image reveals the liposome bilayer that is ~<ce:hsp sp="0.10"/>4<ce:hsp sp="0.25"/>nm thick (white arrows, <ce:cross-ref refid="f0010" id="cf0240">Fig. 1</ce:cross-ref>C). Protocells formulated with DOPC lipids resulted in a cargo loading of dextran tetramethylrhodamine (DexRho) at a capacity of ~<ce:hsp sp="0.10"/>13.49<ce:hsp sp="0.25"/>μg and protocells formulated with DOTAP:Chol lipids exhibited a cargo loading capacity of ~<ce:hsp sp="0.10"/>16.12<ce:hsp sp="0.25"/>μg DexRho.</ce:para><ce:para id="p0135" view="all">Protocells with either DOPC or DOTAP:Chol formulations were characterized separately for their release of DexRho cargo, in which separate aliquots were individually incubated in pH solutions ranging from 2 to 10 for durations of 1 to 168<ce:hsp sp="0.25"/>h (<ce:cross-ref refid="t0005" id="cf0245">Table 1</ce:cross-ref><ce:float-anchor refid="t0005"/> and <ce:cross-ref refid="f0010" id="cf0250">Fig. 1</ce:cross-ref>F, G). Both DOPC and DOTAP:Chol formulated protocells revealed an increase in cargo release at pH<ce:hsp sp="0.25"/>7.4 compared to 6.0 that continued through 24 and 48<ce:hsp sp="0.25"/>h, respectively (<ce:cross-ref refid="f0010" id="cf0255">Fig. 1</ce:cross-ref>F, G). Both pH<ce:hsp sp="0.25"/>6 and pH<ce:hsp sp="0.25"/>7.4 simulate pH environments present extracellularly or in endosomal compartments. Additionally, a characterization of DOPC and DOTAP:Chol formulated protocells loaded with DexRho cargo at a full range of pH levels (<ce:cross-ref refid="t0005" id="cf0260">Table 1</ce:cross-ref>) is provided to determine cargo stability under disparate conditions that can occur during unique manufacturing conditions or under highly acidic conditions that are present during cellular inflammatory processes.</ce:para><ce:section id="s0115" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0130"><ce:italic>In vitro</ce:italic> cellular viability is substantial</ce:section-title><ce:para id="p0140" view="all">Cells remain viable following application of protocells formulated with DOTAP:Chol or DOPC. HEK cells were incubated with 10–500<ce:hsp sp="0.25"/>μg/ml protocells formulated with DOTAP:Chol or DOPC containing plasmid DNA encoding the anti-inflammatory cytokine, interleukin-10, and the reporter gene, green fluorescent protein (pDNA-IL-10/GFP; 10<ce:hsp sp="0.25"/>μg/mg protocells) for 24<ce:hsp sp="0.25"/>h. Protocells without cargo served as controls. To examine the effects of DOTAP:Chol or DOPC protocells containing pDNA-IL-10/GFP cargo on cellular viability, flow cytometry was used by applying ethidium-homodimer-1 (EH-1) to stain the cells. EH-1 enters the cell nucleus and intercolates with DNA only in dead or dying cells in which the membrane is breaking down. Thus, EH-1 does not interact with DNA of live cells with intact membranes. Excitation of EH-1 at 528<ce:hsp sp="0.25"/>nm leads to 617<ce:hsp sp="0.25"/>nm emission (red fluorescence), which is detected by the flow cytometer, and each dead cell is counted. The percentage of dead cells is quantified per 10,000 cells. The percent of live cells was determined (<ce:cross-ref refid="f0015" id="cf0265">Fig. 2</ce:cross-ref><ce:float-anchor refid="f0015"/>). Cells left untreated served as an index of basal cell viability, which was observed to be &gt;<ce:hsp sp="0.10"/>98%. To ensure dead cell quantification, a separate group of cells were treated with 0.1% saponin, and only ~<ce:hsp sp="0.10"/>3% remained viable. Protocells formulated with either DOTAP:Chol or DOPC resulted in &lt;<ce:hsp sp="0.10"/>5% dose-related decrease in cell viability compared to live controls and remained stable even at the highest dose of 500<ce:hsp sp="0.25"/>μg/ml. Thus, cells exposed to DOTAP:Chol or DOPC protocells remained healthy, suggesting that DOTAP:Chol or DOPC protocells lack overt toxicity <ce:italic>in vivo</ce:italic>.</ce:para></ce:section><ce:section id="s0120" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0135">Spinal delivery of protocells is well tolerated in an animal model</ce:section-title><ce:para id="p0145" view="all">Light touch sensory threshold assessment is highly sensitive to subtle perturbations in spinal cord homeostasis. Increases in local spinal immune signaling molecules lead to spinal sensitization of pain-related projection neurons resulting in a hypersensitivity to light touch stimuli applied to the body area innervated by axons whose central terminals also project to the affected spinal segment <ce:cross-refs refid="bb0095 bb0100" id="cf0270">[19,20]</ce:cross-refs>. Thus, assessing alterations in light touch thresholds from basal values following central nervous system protocell application can be a timely, robust and reliable <ce:italic>in vivo</ce:italic> examination of protocell early-phase toxicity within the local spinal cord compartment. Baseline (BL) sensory threshold values for both hindpaws were recorded prior to an i.t. injection of DOTAP:Chol or DOPC formulated protocells. Thresholds close to 10<ce:hsp sp="0.25"/>g of stimulus intensity were observed in all rats prior to treatment (<ce:cross-ref refid="f0020" id="cf0275">Fig. 3</ce:cross-ref><ce:float-anchor refid="f0020"/>).</ce:para><ce:para id="p0150" view="all">Following an i.t. injection of 0.01 or 1<ce:hsp sp="0.25"/>mg DOTAP:Chol formulated protocells, a small increase in light touch sensitivity of the left paw was observed at 30<ce:hsp sp="0.25"/>min and rapidly recovered to basal levels and remained stable during a 72<ce:hsp sp="0.25"/>hr observation period (<ce:cross-ref refid="f0020" id="cf0280">Fig. 3</ce:cross-ref>A, B). Normal insignificant basal variations in paw thresholds were observed in 0.01<ce:hsp sp="0.25"/>mg protocell and control (Vehicle) injected rats. Conversely, both 0.01 and 1<ce:hsp sp="0.25"/>mg DOPC formulated protocells induced a small increase in light touch sensitivity (values dropped to &lt;<ce:hsp sp="0.10"/>1.0<ce:hsp sp="0.25"/>g stimulus intensity) in both the left and right hindpaws at 2<ce:hsp sp="0.25"/>h, that mostly recovered to BL values during the remaining 72<ce:hsp sp="0.25"/>h observation period (<ce:cross-ref refid="f0020" id="cf0285">Fig. 3</ce:cross-ref>C, D). The transient 2-hr increase in light touch sensitivity following DOPC formulated protocells was unexpected given reports show that <ce:italic>in vitro</ce:italic>, DOPC toxicity is virtually absent. However, <ce:italic>in vivo</ce:italic> subtle changes in the local spinal milieu may occur to a greater extent that alters early-phase toxicity and corresponding neuronal processing of normal sensory stimuli. Nevertheless, normal body weight gain was observed in all rats throughout an 8<ce:hsp sp="0.25"/>week observation period during which time, animals remained active and well-groomed (<ce:cross-ref refid="f0020" id="cf0290">Fig. 3</ce:cross-ref>E). Taken together, these data support that i.t. administration of DOTAP:Chol, lack alterations from normal sensory processing and both DOTAP:Chol and DOPC formulated protocells are well-tolerated in the peri-spinal region of rats.</ce:para></ce:section><ce:section id="s0125" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0140">Intrathecal (i.t.) DNA delivered by DOTAP:Chol or DOPC protocells remains closely associated with meninges</ce:section-title><ce:para id="p0155" view="all">Non-coding 18<ce:hsp sp="0.25"/>bp oligonucleotide DNA labeled with the fluorophore, FAM (Ex/Em 492/517<ce:hsp sp="0.25"/>nm; green) delivered by either DOTAP:Chol or DOPC formulated protocells remained closely associated with the cells of the meningeal layer in the spinal cord, but did not penetrate tissue parenchyma. A representative spinal tissue section near the i.t. injection site, revealed DOTAP:Chol protocells containing FAM-tagged DNA (green) in/adjacent to the meningeal layer (<ce:cross-ref refid="f0025" id="cf0295">Fig. 4</ce:cross-ref>A–D<ce:float-anchor refid="f0025"/>), with cellular nuclei counter-stained with the nuclear specific fluorophore, DAPI. Glial cell astrocyte processes and endfeet (astrocytes stained for glial fibrillary acidic protein, GFAP; red) are typically present at the neural-pial meningeal interface, which are capable of taking up extracellular material. Yet, no co-localization of FAM-tagged DNA protocell cargo within astrocytes was observed (<ce:cross-ref refid="f0025" id="cf0300">Fig. 4</ce:cross-ref>A, white arrow). However, immune-relevant macrophage and microglia that normally reside in meninges and at the neural-pial interface are highly efficient phagocytic cells. Indeed, FAM-tagged DNA containing protocells robustly co-localized with macrophages/microglia (stained for CD11b antigen expression; red) in the meningeal peri-spinal region. Co-localization appears yellow (<ce:cross-ref refid="f0025" id="cf0305">Fig. 4</ce:cross-ref>B, white arrow). While microglia are present (red) in the deeper spinal parenchyma, FAM-tagged DNA is absent (<ce:cross-ref refid="f0025" id="cf0310">Fig. 4</ce:cross-ref>B).</ce:para><ce:para id="p0160" view="all">Caspase-3 is a well-characterized enzyme that plays a critical role in the late stages of programmed cell death (apoptosis). Immunohistochemical detection of Caspase-3 (red) was entirely absent in the spinal cords and brains of rats where DOTAP:Chol formulated protocells were present. A representative image of protocells containing FAM-tagged DNA (green) in the meninges reveals no positive Caspase-3 immunoreactivity at 8<ce:hsp sp="0.25"/>weeks following i.t. injection (<ce:cross-ref refid="f0025" id="cf0315">Fig. 4</ce:cross-ref>C). Confocal examination of meningeal macrophage/microglial cells immunostained for expression of ED1, a marker for active immune cells, revealed that DOTAP:Chol protocells containing FAM-tagged DNA were closely associated with the DAPI-stained peri-nuclear area of ED1 expressing cells (<ce:cross-ref refid="f0025" id="cf0320">Fig. 4</ce:cross-ref>D, white arrow).</ce:para><ce:para id="p0165" view="all">To ascertain whether the 18-bp DNA cargo remains associated <ce:italic>in vivo</ce:italic> with mesoporous silica liposome-supported bilayers, DOTAP:Chol liposomes were labeled with Alexa fluor-647 and adsorbed to silica cores loaded with FITC-labeled 18-bp DNA. Rats were given a single spinal i.t. injection of protocells (1<ce:hsp sp="0.25"/>mg) and sacrificed 72<ce:hsp sp="0.25"/>h later to identify protocell lipid bilayers colocalized to the DNA cargo under confocal microscopy. DNA cargo (green) is robustly observed in the meninges surrounding the i.t. injection site (<ce:cross-ref refid="f0025" id="cf0325">Fig. 4</ce:cross-ref>E), and DOTAP:Chol supported liposomes (red) are identified in the peri-spinal meninges (<ce:cross-ref refid="f0025" id="cf0330">Fig. 4</ce:cross-ref>F). Light microscopy reveals the spinal tissue architecture (<ce:cross-ref refid="f0025" id="cf0335">Fig. 4</ce:cross-ref>G) and an overlay of the confocal fluorescent image reveals clear colocalization of DNA cargo with liposomes (yellow) (<ce:cross-ref refid="f0025" id="cf0340">Fig. 4</ce:cross-ref>H), suggesting that the protocell-cargo formulation is stable for 72<ce:hsp sp="0.25"/>h <ce:italic>in vivo</ce:italic>.</ce:para></ce:section><ce:section id="s0130" view="all"><ce:label>3.4</ce:label><ce:section-title id="st0145">In vivo biodistribution of protocells</ce:section-title><ce:para id="p0170" view="all">Eight weeks following i.t. injection, protocells remain in the CNS and are not found in peripheral tissue. As the animals appeared to experience no adverse effects from DOTAP:Chol or DOPC formulated protocells, even at the highest dose, the biodistribution of protocells within and outside of the central nervous system (CNS) was quantified. In these experiments, rats received an i.t. injection of DOTAP:Chol or DOPC protocells loaded with FAM (1<ce:hsp sp="0.25"/>μg FAM 18<ce:hsp sp="0.25"/>bp DNA oligomer/1<ce:hsp sp="0.25"/>mg protocells), and tissues were harvested 2, 4, and 8<ce:hsp sp="0.25"/>weeks later. Blood, the immune organs (cervical lymph nodes, thymus and spleen), the filtering organs (kidney and liver), as well as sections from the brain, cervical, thoracic and lumbar spinal cord were examined to quantify protocells by spectral microscopy analysis that allows computerized de-convolution and quantification of the true FAM-signal from background autofluorescence (<ce:cross-ref refid="f0030" id="cf0345">Fig. 5</ce:cross-ref><ce:float-anchor refid="f0030"/> and <ce:cross-ref refid="t0010" id="cf0350">Table 2</ce:cross-ref><ce:float-anchor refid="t0010"/>).</ce:para><ce:para id="p0175" view="all">The blood was negative for FAM detection (data not shown). The highest amount of FAM levels at 72<ce:hsp sp="0.25"/>h post-DOPTAP:Chol or DOPC protocell injection was observed at the i.t. injection site in the lumbar spinal cord, which significantly decreased by 8<ce:hsp sp="0.25"/>weeks (<ce:cross-ref refid="f0030" id="cf0355">Fig. 5</ce:cross-ref>B). Only DOPC formulated protocells containing FAM-tagged DNA accumulated in the brain by 8<ce:hsp sp="0.25"/>weeks (<ce:cross-ref refid="f0030" id="cf0360">Fig. 5</ce:cross-ref>A). Thus, differences in the biodistribution between the two protocell lipid formulations were observed. Also at 8<ce:hsp sp="0.25"/>weeks, the DOTAP:Chol protocell FAM signal had diminished and was only significant locally, near the injection site, suggesting that DOTAP:Chol formulated protocells may be optimal to maintain localized drug effects, while leaving the brain and the body primarily undisturbed.</ce:para><ce:para id="p0180" view="all">Outside the central nervous system, FAM signal was negligible including in the liver and kidney. At 72<ce:hsp sp="0.25"/>h, a minor but significant amount of FAM was detected in the thymus following treatment of both DOTAP:Chol and DOPC formulated protocells. The data represented in <ce:cross-ref refid="f0030" id="cf0365">Fig. 5</ce:cross-ref>A and B are included in <ce:cross-ref refid="t0005" id="cf0370">Table 1</ce:cross-ref> to provide relative comparisons in FAM detection levels with respect to FAM levels observed in other tissue regions that in most cases, appear negligible. These data additionally suggest that a large amount of protocells escape the intrathecal compartment and are eliminated within 3<ce:hsp sp="0.25"/>days, as protocells are absent from these tissue systems at this timepoint.</ce:para></ce:section><ce:section id="s0135" view="all"><ce:label>3.5</ce:label><ce:section-title id="st0150">Protocell IL-10 gene delivery leads to robust transgene expression</ce:section-title><ce:para id="p0185" view="all">Transfection of HEK cells with a bicistronic plasmid containing the gene for IL-10 and GFP successfully resulted in the expression of IL-10 (<ce:cross-ref refid="f0035" id="cf0375">Fig. 6</ce:cross-ref>A<ce:float-anchor refid="f0035"/>) as well as GFP (<ce:cross-ref refid="f0035" id="cf0380">Fig. 6</ce:cross-ref>C, inset), indicating functional IL-10 transgene expression in GFP expressing HEK cells. Protocells formulated with either DOTAP:Chol or DOPC and loaded with plasmid DNA encoding the IL-10 gene alone (pDNA-IL-10) or in combination with the reporter gene, pDNA-IL-10/GFP, were incubated with HEK cells to examine transgene IL-10 protein expression. It is important to note that HEK cells do not produce IL-10 protein thus providing a reliable assay to quantify transgene-specific IL-10 gene activation. Surprisingly, only those protocells formulated with DOTAP:Chol containing pDNA-IL-10 or pDNA-IL-10/GFP resulted in a robust dose-dependent increase in protein IL-10 levels compared to untreated controls, with the greatest amount of protein (~<ce:hsp sp="0.10"/>900<ce:hsp sp="0.25"/>pg/ml) produced following incubation with 500<ce:hsp sp="0.25"/>μg/ml DOTAP:Chol formulated protocells. In contrast, IL-10 protein from transgene IL-10 delivered by DOPC protocells containing either pDNA-IL-10 or pDNA-IL-10-GFP was significantly lower and reached maximal values of no greater than 100<ce:hsp sp="0.25"/>pg/ml. Additionally, naked pDNA-IL-10 or DOTAP:Chol<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>pDNA-IL-10 resulted a dramatically lower levels of IL-10 protein expression (<ce:cross-ref refid="f0035" id="cf0385">Fig. 6</ce:cross-ref>D), suggesting that protocells improve the transfection efficiency of pDNA-IL-10 and that liposomes alone are significantly less efficient.</ce:para></ce:section><ce:section id="s0140" view="all"><ce:label>3.6</ce:label><ce:section-title id="st0155">Protocells are functionally effective as gene delivery platforms</ce:section-title><ce:para id="p0190" view="all">Given that IL-10 transgene delivered by DOTAP:Chol formulated protocells yielded robust transgene-derived IL-10 protein levels in cell culture (<ce:cross-ref refid="f0035" id="cf0390">Fig. 6</ce:cross-ref>) and DOTAP:Chol protocells appeared to show minimal toxicity <ce:italic>in vivo</ce:italic> (<ce:cross-ref refid="f0020" id="cf0395">Fig. 3</ce:cross-ref>), we next asked whether DOTAP:Chol formulated protocells containing pDNA-IL-10 could act therapeutically by delivering sufficient amounts of the IL-10 transgene to suppress light touch hypersensitivity (allodynia), a neuropathic condition mediated by sensitization of spinal neurons that communicate to brain areas about pain-related stimuli. Allodynia occurs when non-painful stimuli are coded as painful. Following BL assessment of withdrawal behavior to light touch tactile stimuli, rats underwent either sham surgery or CCI of the sciatic nerve. Clear development of allodynia was observed 3 and 10<ce:hsp sp="0.25"/>days later (<ce:cross-ref refid="f0040" id="cf0400">Fig. 7</ce:cross-ref>A, B<ce:float-anchor refid="f0040"/>). On Day 10, rats received an i.t. injection of DOTAP:Chol formulated protocells containing pDNA-IL-10, pDNA-control (non-coding DNA), or equivolume vehicle (20<ce:hsp sp="0.25"/>μl). While sham rats remained stably non-allodynic, a rapid and complete reversal from neuropathic allodynia was observed in IL-10 treated rats. Neuropathic rats injected with i.t. control pDNA or vehicle remained stably allodynic throughout a 26-day timecourse. It is important to note that a prior report demonstrated an equivalent dose of i.t. naked pDNA-IL-10 lacks efficacy to reverse allodynia <ce:cross-ref refid="bb0060" id="cf0405">[12]</ce:cross-ref>. Taken together, these data show that pDNA-IL-10 delivered to the peri-spinal regions by DOTAP:Chol protocells was able to reverse allodynia to BL levels for almost 2<ce:hsp sp="0.25"/>weeks. These data support that the production of IL-10 protein from pDNA-IL-10 transgene loaded on protocells is functionally and physiologically effective in reversing pain thresholds.</ce:para><ce:para id="p0195" view="all">The toxicity profile of protocells is minimal, as they do not lead to subtle perturbations in cell stress, as assessed by the production of nitric oxide (NO). In order to assess subtle and transient cell-stress responses to the identical DOTAP:Chol protocell formulation examined for <ce:italic>in vivo</ce:italic> spinal gene therapy, cultured macrophage cells (Raw 264.7) were examined, given the observed <ce:italic>in vivo</ce:italic> spinal co-localization of DOTAP:Chol protocells with macrophages/microglial cells, as described above in <ce:cross-ref refid="f0025" id="cf0410">Fig. 4</ce:cross-ref>. Macrophages were assayed for NO following a 2-hour incubation with whole protocells or the component silica core and lipid (DOTAP:Chol) (<ce:cross-ref refid="f0040" id="cf0415">Fig. 7</ce:cross-ref>C). Lipopolysaccharide (LPS) was included, as it is known to produce robust enhancement of NO in this cell line <ce:cross-refs refid="bb0155 bb0160 bb0165 bb0170" id="cf0420">[31–34]</ce:cross-refs>. As expected, cells incubated with LPS for 10<ce:hsp sp="0.25"/>min produced increased levels of NO compared to untreated controls. However, similar basal NO levels were observed between untreated controls, whole protocells, silica cores and DOTAP:Chol lipid, suggesting that these materials do not generate transient or even subtle cell stress events.</ce:para></ce:section></ce:section><ce:section id="s0145" view="all"><ce:label>4</ce:label><ce:section-title id="st0160">Discussion</ce:section-title><ce:para id="p0200" view="all">Our results demonstrate that mesoporous silica particle cores that support either DOTAP:Chol or DOPC formulated liposomes (protocells) release cargo (Dextran Rhodamine; a negatively charged fluorophore) when exposed to a range of pH values, with greater cargo release occurring at pH<ce:hsp sp="0.25"/>7.4 and higher. Interestingly, protocell cargo is optimally retained at pH<ce:hsp sp="0.25"/>6.0, while lower pH values again induce increased cargo release. Both formulations resulted in high cellular-viability values (&gt;<ce:hsp sp="0.10"/>90%) following a 50-fold dose range exposure (<ce:cross-refs refid="f0010 f0015" id="cf0425">Figs. 1 and 2</ce:cross-refs>). Additionally, peri-spinal application (subarachnoid, intrathecal; i.t.) of either DOTAP:Chol protocells or DOPC formulated protocells in separate groups of rats resulted in minimal sensory changes. Subtle but significant differences in hindpaw sensory threshold values were generally lower in DOPC protocell-treated rats at 2<ce:hsp sp="0.25"/>h compared to thresholds of DOTAP:Chol protocell treated rats (<ce:cross-ref refid="f0020" id="cf0430">Fig. 3</ce:cross-ref>A–D). Importantly, assessment for threshold changes in light mechanical touch from baseline is a sensitive surrogate indicator for physiological spinal cord perturbations involving early-phase inflammatory processes <ce:cross-ref refid="bb0175" id="cf0435">[35]</ce:cross-ref> including the generation of nitric oxide (NO) with consequent reactive oxygen species formation and proinflammatory cytokine production (<ce:italic>e.g.</ce:italic> interlukin-1beta, IL-1β and tumor necrosis factor-alpha, TNF-α) <ce:cross-refs refid="bb0095 bb0105 bb0180 bb0185 bb0190 bb0195" id="cf0440">[19,21,36–39]</ce:cross-refs>. The damaging effects of subtle inflammatory processes often go undetected when only employing overt observations for general health measures such as ambulatory function and body weight gain. In studies reported here, an 8-wk observation period for body weight gain revealed no differences between i.t. saline treated and DOTAP:Chol protocell and DOPC protocell-treated animals (<ce:cross-ref refid="f0020" id="cf0445">Fig. 3</ce:cross-ref>E). Spinal immunohistochemical examination of DOTAP:Chol protocells containing DNA revealed clear co-localization with macrophage/microglial cells at the spinal-meningeal interface (<ce:cross-ref refid="f0025" id="cf0450">Fig. 4</ce:cross-ref>D), with a complete lack of cell death, as indicated by the absence of immunoreactivity for the late phase necessary apoptotic enzyme, Caspase-3 (<ce:cross-ref refid="f0025" id="cf0455">Fig. 4</ce:cross-ref>C). Cargo are co-localized with mesoporous silica-supported DOTAP:Chol liposomes observed 3<ce:hsp sp="0.25"/>days following i.t. protocell injection (<ce:cross-ref refid="f0025" id="cf0460">Fig. 4</ce:cross-ref>H).</ce:para><ce:para id="p0205" view="all">While these findings support that DOTAP:Chol protocells offer a significant degree of biocompatibility, clear differences were observed <ce:italic>in vivo</ce:italic> between the biodistribution of DOTAP:Chol formulated and DOPC formulated protocells. Both DOTAP:Chol and DOPC formulated protocell cargo surrounding the spinal cord injection site were identified for as long as 8<ce:hsp sp="0.25"/>weeks following administration (<ce:cross-ref refid="f0030" id="cf0465">Fig. 5</ce:cross-ref>B), but only DOPC protocells revealed an increased spread to brain observed at 8<ce:hsp sp="0.25"/>weeks (<ce:cross-ref refid="f0030" id="cf0470">Fig. 5</ce:cross-ref>A and <ce:cross-ref refid="t0010" id="cf0475">Table 2</ce:cross-ref>). Furthermore, IL-10 transgene expression <ce:italic>in vitro</ce:italic> was significantly greater following cellular incubation with DOTAP:Chol-protocells containing plasmid DNA encoding IL-10 (pDNA-IL-10) than cells incubated with DOPC protocells containing pDNA-IL-10 cargo (<ce:cross-ref refid="f0035" id="cf0480">Fig. 6</ce:cross-ref>A, B). Additionally, DOTAP:Chol protocells revealed superior transfection efficiency to naked pDNA-IL-10 or DOTAP:Chol liposomes alone (<ce:cross-ref refid="f0035" id="cf0485">Fig. 6</ce:cross-ref>D).</ce:para><ce:para id="p0210" view="all">Based on the overall profile of DOTAP:Chol protocells as highly biocompatible, localized biodistribution and greater transgene expression, DOTAP:Chol protocells loaded with pDNA-IL-10 cargo were examined for their <ce:italic>in vivo</ce:italic> therapeutic potential as a novel non-viral gene transfer vector delivered to the spinal cord to treat peripheral neuropathic pain. Compared to various control-treated rats, i.t. injections of DOTAP:Chol pDNA-IL-10 protocells resulted in robust reversal of allodynia for as long as 12<ce:hsp sp="0.25"/>days (<ce:cross-ref refid="f0040" id="cf0490">Fig. 7</ce:cross-ref>A, B). Importantly, inflammatory nitric oxide, used as a sensitive and specific factor indicative of cell stress, was virtually absent in macrophages exposed to the composite DOTAP:Chol protocell formulation or its constitutive components (<ce:cross-ref refid="f0040" id="cf0495">Fig. 7</ce:cross-ref>C).</ce:para><ce:para id="p0215" view="all">A schematic illustration of the mesoporous silica supported lipid bilayer (protocells) showing the theoretical loading characteristics of the diagnostic tools used in these studies (DexRho, 18-bp DNA) or the therapeutic agent, pDNA-IL-10 is shown (<ce:cross-ref refid="f0045" id="cf0500">Fig. 8</ce:cross-ref><ce:float-anchor refid="f0045"/>). The 5.9<ce:hsp sp="0.25"/>kb pDNA-IL-10 is likely supercoiled and interacts both in between the silica core and the lipid bilayer, but also at the surface of the positively charged DOTAP:Chol lipid bilayer. In future studies, next-generation mesoporous silica cores engineered with ultra large pores are predicted to greatly improve the therapeutic gene delivery as other groups have successfully demonstrated <ce:cross-refs refid="bb0200 bb0205" id="cf0505">[40,41]</ce:cross-refs>. It is important to note that the mesoporous silica cores used in these studies increase loading capacity of small molecules that serve a diagnostic function, or can enhance therapeutic efficacy of drugs or transgene uptake.</ce:para><ce:para id="p0220" view="all">The data provided in this report show that protocells are capable of prolonged drug delivery, as DOTAP:Chol-protocells release ~<ce:hsp sp="0.10"/>35–40% of negatively charged cargo at pH<ce:hsp sp="0.25"/>7.4, which mimics CSF as well as extracellular pH, during a 1<ce:hsp sp="0.25"/>week timeframe. Protocells at pH<ce:hsp sp="0.25"/>6.0 only release ~<ce:hsp sp="0.10"/>25–30% of cargo within a 72<ce:hsp sp="0.25"/>h time frame, which although speculative, may be exploited when increased cargo retention is desired during late endosomal trafficking. Importantly, a substantial amount of protocell cargo content remains for as long as 1<ce:hsp sp="0.25"/>week, supporting the possibility that enduring protocell cargo release for many weeks can be achieved resulting in long-duration therapeutic transgene efficacy. This is particularly desirable for the treatment of chronic CNS diseases such as chronic neuropathic pain. Future studies will determine whether trafficking to late lysosomes containing ~<ce:hsp sp="0.10"/>3–4<ce:hsp sp="0.25"/>pH values results in a significant amount of cargo release. While the mechanism of protocell escape from lysosomes remains unknown, pH-dependent cargo release may support an approach that optimizes cargo delivery to specific intracellular compartments with low pH environments. Confocal microscopy shown in the current report demonstrates that protocell cargo is indeed present within and adjacent to cellular nuclei of macrophages in the spinal meninges surrounding the injection site. These observations suggest that while protocells do not necessarily need to enter the nucleus for transgene host cell gene activation, nuclear localization is possible.</ce:para><ce:para id="p0225" view="all">While mesoporous silica particles have been widely studied and characterized for <ce:italic>in vitro</ce:italic> biocompatibility, high cargo capacity, tunable pore diameters and surface chemistries <ce:cross-refs refid="bb0090 bb0210 bb0215 bb0220 bb0225 bb0230 bb0235" id="cf0510">[18,42–47]</ce:cross-refs>, this report is the first <ce:italic>in vivo</ce:italic> demonstration of protocells as non-toxic and functionally capable non-viral spinal gene therapy vectors. The therapeutic application of protocells is highly beneficial for several critical reasons. First, factors indicative of cell stress (nitric oxide; NO) is absent following exposure to whole protocells or the components of protocells (<ce:cross-ref refid="f0040" id="cf0515">Fig. 7</ce:cross-ref>C). Inducible NO is a factor that is rapidly produced following cell stress and inflammation known to mediate the induction of reactive oxygen species further contributing to cell stress <ce:cross-refs refid="bb0240 bb0245" id="cf0520">[48,49]</ce:cross-refs>. Proinflammatory IL-1β and TNF-α typically contribute to additional NO production, creating ongoing inflammatory processes. Second, the current data also reveal a lack of <ce:italic>in vivo</ce:italic> spinal perturbations (<ce:italic>e.g.</ce:italic> inflammatory responses) following spinal protocell application (<ce:cross-ref refid="f0020" id="cf0525">Fig. 3</ce:cross-ref>A–D). Indeed, sensory hindpaw response-thresholds remained unchanged from baseline, a physiological ‘read-out’ of healthy conditions. Third, we further demonstrate that spinal tissue immunohistochemical examination indicated the complete absence of activated Caspase-3 (<ce:cross-ref refid="f0025" id="cf0530">Fig. 4</ce:cross-ref>C), a critical enzyme that mediates programmed cell death <ce:cross-ref refid="bb0250" id="cf0535">[50]</ce:cross-ref>. Additionally, we speculate that a large percentage of i.t. protocells escape to the blood circulation where they are cleared by the liver and kidneys with 24h, as protocells or their cargo was absent from peripheral tissues examined at 72<ce:hsp sp="0.25"/>h. Close behavioral assessment, from minutes (30<ce:hsp sp="0.25"/>min), to hours (1, 2, 3, 24 &amp; 72), to weeks (up to 8<ce:hsp sp="0.25"/>weeks) strongly supports a lack of adverse reactivity (normal sensory profiles and weight gain). Collectively, these properties of protocells make them attractive platforms for non-viral drug or gene delivery using a range of formulations. In the current study, this first-generation protocell supporting a DOTAP:Chol lipid bilayer appears to be functionally effective as spinal gene delivery vehicles for pain-related therapeutic purposes.</ce:para><ce:para id="p0230" view="all">The majority of worldwide clinical trials using non-viral gene delivery techniques currently represents ~<ce:hsp sp="0.10"/>27% of the total gene therapy clinical trials <ce:cross-ref refid="bb0255" id="cf0540">[51]</ce:cross-ref>, with these trials mostly applying naked plasmid DNA, and none aimed at neuropathic pain control. However, the examination of gene therapy applications for neuropathic pain in animal models has significantly increased during the past dozen years, with candidate gene products intended to disrupt pain-associated biochemical changes, or themselves, act as analgesics <ce:cross-ref refid="bb0260" id="cf0545">[52]</ce:cross-ref>. These trends point to the extraordinary need for new approaches toward developing novel pain therapeutics, as currently available drugs are minimally effective for pathological pain. Thus, the emerging area of CNS gene therapeutics for pain control is rapidly growing.</ce:para><ce:para id="p0235" view="all">Neuropathic pain results from pathology in the nervous system and arises from aberrant signals in sensitized injured axons in the peripheral and/or central nervous system <ce:cross-ref refid="bb0265" id="cf0550">[53]</ce:cross-ref>. The anti-inflammatory cytokine, IL-10, leads to exceptionally robust suppression of several pain-related conditions including allodynia in various animal models <ce:cross-ref refid="bb0270" id="cf0555">[54]</ce:cross-ref>. Allodynia, as assessed in this study, is a pathological sensory condition whereby non-noxious stimuli such as mechanical light touch to the skin are processed as painful <ce:cross-ref refid="bb0275" id="cf0560">[55]</ce:cross-ref>, and spinal IL-10 gene therapy results in prolonged suppression of chronic allodynia <ce:cross-ref refid="bb0280" id="cf0565">[56]</ce:cross-ref>. Indeed, non-viral naked plasmid DNA or polymer-encapsulated gene therapy to control neuropathic pain has been successfully demonstrated in animal models of neuropathic pain <ce:cross-refs refid="bb0060 bb0065 bb0115" id="cf0570">[12,13,23]</ce:cross-refs>. Interestingly, these non-viral approaches are thought to harness phagocytic innate immune cells that are present at low levels in the peri-spinal meninges and subarachnoid space <ce:cross-ref refid="bb0060" id="cf0575">[12]</ce:cross-ref>, as an increase in phagocytic macrophages accumulate surrounding the intrathecal lumbar spinal injection site. However, the transgene dose, release rate and cellular targets are constrained by the method of gene delivery used in these prior studies. Conversely, increased transgene dose (cargo retention) and greater flexibility in DNA release rate may be achieved in future-generation protocells used as delivery platforms.</ce:para><ce:para id="p0240" view="all">The prior established efficacy of IL-10 for pain control allows comparisons with novel gene delivery approaches, like protocells, that result in therapeutic pain-suppression, and enables one to identify new and improved gene and drug carrier platforms with promising clinical applications. Our data demonstrate that this first-generation DOTAP:Chol protocell formulation is a highly feasible carrier platform for spinal gene therapy. It is important to note that developing next-generation protocell platforms are aimed at delivering cargo that act to stimulate transgene uptake; a multi-therapy approach, and may be superior to existing approaches.</ce:para></ce:section><ce:section id="s0150" view="all"><ce:label>5</ce:label><ce:section-title id="st0165">Conclusions</ce:section-title><ce:para id="p0245" view="all">This work characterizes the <ce:italic>in vitro</ce:italic> cell stress and <ce:italic>in vivo</ce:italic> physiological profile of liposomes fused on mesoporous silica particles, and examines their use as gene therapeutic vectors delivered to the spinal cord. These liposome-supported mesoporous silica particle constructs are referred to as protocells, which act to retain and protect DNA cargo used in these studies. The advantage of applying protocells as cargo delivery systems (drug and genes) lies not only in their potential for exceptional cargo capacity, but also, as demonstrated in this report, in their high and enduring biocompatibility within the CNS. As non-viral vectors, protocells allow transgenes of interest to remain physiologically functional. Most intriguing is the potential application of this approach to other CNS diseases <ce:cross-refs refid="bb0285 bb0290" id="cf0580">[57,58]</ce:cross-refs> where future-generation protocells can be engineered for cell-specific targeting and tunable release rates. The data in this report demonstrate that protocells loaded with the IL-10 transgene and delivered peri-spinally produce robust pain suppression supporting prior reports that spinal IL-10 gene therapy leads to a reduction of pain <ce:cross-refs refid="bb0060 bb0065 bb0070 bb0080 bb0115 bb0295 bb0300" id="cf0585">[12–14,16,23,59,60]</ce:cross-refs>. Thus, protocells offer a potentially new drug delivery vessel to the CNS with intrinsic flexibility to tailor drug therapy.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0170">Acknowledgments</ce:section-title><ce:para id="p0250" view="all">The authors would like to thank Linda C. Saland (Department of Neurosciences, University of New Mexico, Albuquerque, New Mexico) for her kind advice regarding tissue immunohistochemistry studies, Becky Lee and Genevieve Phillips (Fluorescence Microscopy Shared Resource, University of New Mexico, Albuquerque, New Mexico) for their assistance in spectral imaging and Tamara Roitbak (Department of Neurosurgery, Health Sciences Center, University of New Mexico) for assisting with confocal imaging. This work was funded by a <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Science Foundation</ce:grant-sponsor> IGERT grant: Integrating Nanotechnology with Cell Biology and Neuroscience (<ce:grant-number refid="gts0005">DGE 0549500</ce:grant-number>), and a grant from the <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Institute on Drug Abuse</ce:grant-sponsor>: #<ce:grant-number refid="gts0010">2RO1 0181549500</ce:grant-number>.</ce:para><ce:para id="p0255" view="all">CJB received support from the <ce:grant-sponsor id="gts0015" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">NCI Cancer Nanotechnology Platform Partnership</ce:grant-sponsor> grant <ce:grant-number refid="gts0015">1U01CA151792-01</ce:grant-number>; the <ce:grant-sponsor id="gts0020" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">U.S. Department of Energy, Office of Basic Energy Sciences, Division of Materials Sciences and Engineering</ce:grant-sponsor>; and the <ce:grant-sponsor id="gts0025" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Sandia National Laboratories' Laboratory Directed Research and Development (LDRD)</ce:grant-sponsor> program. Sandia is a multiprogram laboratory operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Company, for the <ce:grant-sponsor id="gts0030" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">US Department of Energy's National Nuclear Security Administration</ce:grant-sponsor> under contract <ce:grant-number refid="gts0030">DE-AC04-94AL85000</ce:grant-number>. The authors report no conflict of interest.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st1010">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Edelstein</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Abedi</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wixon</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene therapy clinical trials worldwide to 2007–an update</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J Gene Med</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:issue-nr>10</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>833</sb:first-page><sb:last-page>842</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Kaiser</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene therapists celebrate a decade of progress</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>334</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>29</sb:first-page><sb:last-page>30</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.C.</ce:given-name><ce:surname>Perez-Martinez</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Guerra</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Posadas</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Cena</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Barriers to non-viral vector-mediated gene delivery in the nervous system</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:issue-nr>8</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1843</sb:first-page><sb:last-page>1858</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Morille</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Passirani</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Vonarbourg</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Clavreul</ce:surname></sb:author><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Benoit</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Progress in developing cationic vectors for non-viral systemic gene therapy against cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:issue-nr>24–25</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>3477</sb:first-page><sb:last-page>3496</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.G.</ce:given-name><ce:surname>Trewyn</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Giri</ce:surname></sb:author><sb:author><ce:surname>Slowing</ce:surname><ce:suffix>II</ce:suffix></sb:author><sb:author><ce:given-name>V.S.</ce:given-name><ce:surname>Lin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Chem. Commun. (Camb.)</sb:maintitle></sb:title></sb:series><sb:issue-nr>31</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>3236</sb:first-page><sb:last-page>3245</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Rogers</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Rush</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Control. Release</sb:maintitle></sb:title><sb:volume-nr>157</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>183</sb:first-page><sb:last-page>189</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.J.</ce:given-name><ce:surname>Park</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Park</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Oxidative stress and pro-inflammatory responses induced by silica nanoparticles in vivo and in vitro</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Toxicol. Lett.</sb:maintitle></sb:title><sb:volume-nr>184</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>18</sb:first-page><sb:last-page>25</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.P.</ce:given-name><ce:surname>Hudson</ce:surname></sb:author><sb:author><ce:given-name>R.F.</ce:given-name><ce:surname>Padera</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>D.S.</ce:given-name><ce:surname>Kohane</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The biocompatibility of mesoporous silicates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:issue-nr>30</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>4045</sb:first-page><sb:last-page>4055</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.E.</ce:given-name><ce:surname>Ashley</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Carnes</ce:surname></sb:author><sb:author><ce:given-name>G.K.</ce:given-name><ce:surname>Phillips</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Padilla</ce:surname></sb:author><sb:author><ce:given-name>P.N.</ce:given-name><ce:surname>Durfee</ce:surname></sb:author><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Brown</ce:surname></sb:author><sb:author><ce:given-name>T.N.</ce:given-name><ce:surname>Hanna</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Phillips</ce:surname></sb:author><sb:author><ce:given-name>M.B.</ce:given-name><ce:surname>Carter</ce:surname></sb:author><sb:author><ce:given-name>N.J.</ce:given-name><ce:surname>Carroll</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Jiang</ce:surname></sb:author><sb:author><ce:given-name>D.R.</ce:given-name><ce:surname>Dunphy</ce:surname></sb:author><sb:author><ce:given-name>C.L.</ce:given-name><ce:surname>Willman</ce:surname></sb:author><sb:author><ce:given-name>D.N.</ce:given-name><ce:surname>Petsev</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Evans</ce:surname></sb:author><sb:author><ce:given-name>A.N.</ce:given-name><ce:surname>Parikh</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Chackerian</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Wharton</ce:surname></sb:author><sb:author><ce:given-name>D.S.</ce:given-name><ce:surname>Peabody</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Mater.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>389</sb:first-page><sb:last-page>397</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Tarn</ce:surname></sb:author><sb:author><ce:given-name>C.E.</ce:given-name><ce:surname>Ashley</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Xue</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Carnes</ce:surname></sb:author><sb:author><ce:given-name>J.I.</ce:given-name><ce:surname>Zink</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Acc. Chem. Res.</sb:maintitle></sb:title></sb:series><sb:date>2013</sb:date></sb:issue><ce:doi>10.1021/ar3000986</ce:doi></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Slowing</ce:surname><ce:suffix>II</ce:suffix></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Vivero-Escoto</ce:surname></sb:author><sb:author><ce:given-name>C.W.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>V.S.</ce:given-name><ce:surname>Lin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Drug Deliv. Rev.</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:issue-nr>11</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>1278</sb:first-page><sb:last-page>1288</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>B.M.</ce:given-name><ce:surname>Jekich</ce:surname></sb:author><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author><sb:author><ce:given-name>T.S.</ce:given-name><ce:surname>Hughes</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Seibert</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Chavez</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>13</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.G.</ce:given-name><ce:surname>Soderquist</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>L.C.</ce:given-name><ce:surname>Loram</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Harrison</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Dengler</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>L.D.</ce:given-name><ce:surname>Amer</ce:surname></sb:author><sb:author><ce:given-name>C.S.</ce:given-name><ce:surname>Young</ce:surname></sb:author><sb:author><ce:given-name>M.T.</ce:given-name><ce:surname>Lewis</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Poole</ce:surname></sb:author><sb:author><ce:given-name>M.G.</ce:given-name><ce:surname>Frank</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>841</sb:first-page><sb:last-page>854</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>He</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wieseler-Frank</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>O'Connor</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Martin</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Forsayeth</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Chavez</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, Interleukin-10</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>2136</sb:first-page><sb:last-page>2148</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.S.</ce:given-name><ce:surname>Beutler</ce:surname></sb:author><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Banck</ce:surname></sb:author><sb:author><ce:given-name>C.E.</ce:given-name><ce:surname>Walsh</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Intrathecal gene transger by adeno-associated virus for pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Opin. Mol. Ther.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>431</sb:first-page><sb:last-page>439</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>R.G.</ce:given-name><ce:surname>Soderquist</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Malone</ce:surname></sb:author><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author><sb:author><ce:given-name>T.S.</ce:given-name><ce:surname>Hughes</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Intrathecal polymer-based interleukin-10* gene delivery for neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron Glia Biol.</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>293</sb:first-page><sb:last-page>308</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Jiang</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Ashley</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Electrostatically mediated liposome fusion and lipid exchange with a nanoparticle-supported bilayer for control of surface charge, drug containment, and delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:issue-nr>22</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>7567</sb:first-page><sb:last-page>7569</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Stace-Naughton</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Jiang</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1354</sb:first-page><sb:last-page>1355</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Chaplan</ce:surname></sb:author><sb:author><ce:given-name>F.W.</ce:given-name><ce:surname>Bach</ce:surname></sb:author><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Pogrel</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Chung</ce:surname></sb:author><sb:author><ce:given-name>T.L.</ce:given-name><ce:surname>Yaksh</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Quantitative assessment of tactile allodynia in the rat paw</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci. Methods</sb:maintitle></sb:title><sb:volume-nr>53</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>55</sb:first-page><sb:last-page>63</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>K.K.</ce:given-name><ce:surname>Mehmert</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Hinde</ce:surname></sb:author><sb:author><ce:given-name>L.O.J.</ce:given-name><ce:surname>Harvey</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Martin</ce:surname></sb:author><sb:author><ce:given-name>K.J.</ce:given-name><ce:surname>Tracey</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the Human Immunodeficiency Virus-1 (HIV-1) envelope glycoprotein, gp120</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>861</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>105</sb:first-page><sb:last-page>116</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>O'Connor</ce:surname></sb:author><sb:author><ce:given-name>K.T.</ce:given-name><ce:surname>Nguyen</ce:surname></sb:author><sb:author><ce:given-name>C.B.</ce:given-name><ce:surname>Armstrong</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Twining</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Gaykema</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Holguin</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Martin</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Intrathecal HIV-1 envelope glycoprotein gp120 enhanced pain states mediated by spinal cord proinflammatory cytokines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>2808</sb:first-page><sb:last-page>2819</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Bennett</ce:surname></sb:author><sb:author><ce:given-name>K.Y.</ce:given-name><ce:surname>Xie</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pain</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>87</sb:first-page><sb:last-page>107</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>T.R.</ce:given-name><ce:surname>Hughes</ce:surname></sb:author><sb:author><ce:given-name>B.M.</ce:given-name><ce:surname>Jekich</ce:surname></sb:author><sb:author><ce:given-name>M.G.</ce:given-name><ce:surname>Frank</ce:surname></sb:author><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author><sb:author><ce:given-name>L.H.</ce:given-name><ce:surname>Levkoff</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>P.E.</ce:given-name><ce:surname>Cruz</ce:surname></sb:author><sb:author><ce:given-name>T.R.</ce:given-name><ce:surname>Flotte</ce:surname></sb:author><sb:author><ce:given-name>K.W.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>M.M.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Chavez</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pain</sb:maintitle></sb:title><sb:volume-nr>126</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>294</sb:first-page><sb:last-page>308</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Langer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Drug delivery and targeting</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>392</sb:volume-nr></sb:series><sb:issue-nr>6679 Suppl.</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>5</sb:first-page><sb:last-page>10</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Crook</ce:surname></sb:author><sb:author><ce:given-name>B.J.</ce:given-name><ce:surname>Stevenson</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Dubouchet</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Porteous</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>137</sb:first-page><sb:last-page>143</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Barrett</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Joyner</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Halenda</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The Determination of Pore volume and Area distributions in Porous Substances. I. Computations from Nitrogen isotherms</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>73</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>1951</sb:date></sb:issue><sb:pages><sb:first-page>373</sb:first-page><sb:last-page>380</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Jiang</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Aerosol-assisted self-assembly of single-crystal core/nanoporous shell particles as model controlled release capsules</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>128</sb:volume-nr></sb:series><sb:issue-nr>14</sb:issue-nr><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>4512</sb:first-page><sb:last-page>4513</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Brunauer</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Emmett</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Teller</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adsorption of Gases in Multimolecular Layers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Chem. Soc.</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1938</sb:date></sb:issue><sb:pages><sb:first-page>309</sb:first-page><sb:last-page>319</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Wilkerson</ce:surname></sb:author><sb:author><ce:given-name>K.R.</ce:given-name><ce:surname>Gentry</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Dengler</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Wallace</ce:surname></sb:author><sb:author><ce:given-name>A.A.</ce:given-name><ce:surname>Kerwin</ce:surname></sb:author><sb:author><ce:given-name>M.N.</ce:given-name><ce:surname>Kuhn</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Zvonok</ce:surname></sb:author><sb:author><ce:given-name>G.A.</ce:given-name><ce:surname>Thakur</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Makriyannis</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Behav.</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>155</sb:first-page><sb:last-page>177</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.O.J.</ce:given-name><ce:surname>Harvey</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Efficient estimation of sensory thresholds</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Behav. Res. Methods Instrum. Comput.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1986</sb:date></sb:issue><sb:pages><sb:first-page>623</sb:first-page><sb:last-page>632</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Khan</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Drug Target.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>393</sb:first-page><sb:last-page>404</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.K.</ce:given-name><ce:surname>Lee</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anti-inflammatory effects of eriodictyol in lipopolysaccharide-stimulated raw 264.7 murine macrophages</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch. Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>34</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>671</sb:first-page><sb:last-page>679</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>[33]</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.A.</ce:given-name><ce:surname>Qureshi</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Tan</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Reis</ce:surname></sb:author><sb:author><ce:given-name>M.Z.</ce:given-name><ce:surname>Badr</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Papasian</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Morrison</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Qureshi</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lipids Health Dis.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>177</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>[34]</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.Y.</ce:given-name><ce:surname>Zha</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Mao</ce:surname></sb:author><sb:author><ce:given-name>X.C.</ce:given-name><ce:surname>Lu</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Deng</ce:surname></sb:author><sb:author><ce:given-name>J.F.</ce:given-name><ce:surname>Ye</ce:surname></sb:author><sb:author><ce:given-name>X.W.</ce:given-name><ce:surname>Chu</ce:surname></sb:author><sb:author><ce:given-name>S.X.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Luo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-kappaB-mediated nitric oxide synthase expression</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:issue-nr>8</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>2415</sb:first-page><sb:last-page>2418</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>[35]</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Kawasaki</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>J.-K.</ce:given-name><ce:surname>Cheng</ce:surname></sb:author><sb:author><ce:given-name>R.-R.</ce:given-name><ce:surname>Ji</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1b, interleukin-6, and tumor necrosis factor-a in regulating syntapic and neuronal activity in the superficial spinal cord</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:issue-nr>20</sb:issue-nr><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>5189</sb:first-page><sb:last-page>5194</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>[36]</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Samad</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>Moore</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Sapirstein</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Billet</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Allchorne</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Poole</ce:surname></sb:author><sb:author><ce:given-name>J.V.</ce:given-name><ce:surname>Bonventre</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Interleukin-1b-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>410</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>471</sb:first-page><sb:last-page>475</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>[37]</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Samad</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Broom</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Woolf</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Central neuroimmune interactions after peripheral inflammation: interleukin-1β potentiates synaptic transmission in the spinal cord</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Proc Soc Neurosci</sb:maintitle></sb:title><sb:date>2004</sb:date></sb:edited-book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>[38]</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>van der Maesen</ce:surname></sb:author><sb:author><ce:given-name>F.P.</ce:given-name><ce:surname>Somera</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Macrophage and microglial responses to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci. Res.</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>68</sb:first-page><sb:last-page>78</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>[39]</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Beyond neurons: evidence that immune and glial cells contribute to pathological pain states</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Physiol. Rev.</sb:maintitle></sb:title><sb:volume-nr>82</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>981</sb:first-page><sb:last-page>1011</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>[40]</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Botella</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Corma</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Blesa</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Dong</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Monodispersed mesoporous silica nanoparticles with very large pores for enhanced adsorption and release of DNA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Phys. Chem. B</sb:maintitle></sb:title><sb:volume-nr>113</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1796</sb:first-page><sb:last-page>1804</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>[41]</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Kim</ce:surname></sb:author><sb:author><ce:given-name>H.K.</ce:given-name><ce:surname>Na</ce:surname></sb:author><sb:author><ce:given-name>Y.K.</ce:given-name><ce:surname>Kim</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Ryoo</ce:surname></sb:author><sb:author><ce:given-name>H.S.</ce:given-name><ce:surname>Cho</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Lee</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Jeon</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Ryoo</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Min</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>ACS Nano</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>3568</sb:first-page><sb:last-page>3576</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>[42]</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Bimbo</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Peltonen</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Hirvonen</ce:surname></sb:author><sb:author><ce:given-name>H.A.</ce:given-name><ce:surname>Santos</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Toxicological profile of therapeutic nanodelivery systems</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Drug Metab.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:issue-nr>8</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1068</sb:first-page><sb:last-page>1086</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>[43]</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.W.</ce:given-name><ce:surname>Davis</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Flores</ce:surname></sb:author><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Barrick</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Cox</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Brozik</ce:surname></sb:author><sb:author><ce:given-name>G.P.</ce:given-name><ce:surname>Lopez</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Brozik</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nanoporous microbead supported bilayers: stability, physical characterization, and incorporation of functional transmembrane proteins</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Langmuir</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:issue-nr>7</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>3864</sb:first-page><sb:last-page>3872</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>[44]</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Sackmann</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Supported membranes: scientific and practical applications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>271</sb:volume-nr></sb:series><sb:issue-nr>5245</sb:issue-nr><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>43</sb:first-page><sb:last-page>48</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>[45]</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.P.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Panwar</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Kohli</ce:surname></sb:author><sb:author><ce:surname>Sanjesh</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Liposome-mesoporous silica nanoparticles fused cores: a safer mode of drug carrier</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biomed. Nanotechnol.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>60</sb:first-page><sb:last-page>62</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>[46]</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.L.</ce:given-name><ce:surname>Troutier</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Ladaviere</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>An overview of lipid membrane supported by colloidal particles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Colloid Interf. Sci.</sb:maintitle></sb:title><sb:volume-nr>133</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>21</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>[47]</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.H.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>C.K.</ce:given-name><ce:surname>Yee</ce:surname></sb:author><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Amweg</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>E.L.</ce:given-name><ce:surname>Kendall</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Dattelbaum</ce:surname></sb:author><sb:author><ce:given-name>A.P.</ce:given-name><ce:surname>Shreve</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Brinker</ce:surname></sb:author><sb:author><ce:given-name>A.N.</ce:given-name><ce:surname>Parikh</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Optical detection of ion-channel-induced proton transport in supported phospholipid bilayers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nano Lett.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>8</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>2446</sb:first-page><sb:last-page>2451</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>[48]</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Son</ce:surname></sb:author><sb:author><ce:given-name>Y.K.</ce:given-name><ce:surname>Cheong</ce:surname></sb:author><sb:author><ce:given-name>N.H.</ce:given-name><ce:surname>Kim</ce:surname></sb:author><sb:author><ce:given-name>H.T.</ce:given-name><ce:surname>Chung</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Kang</ce:surname></sb:author><sb:author><ce:given-name>H.O.</ce:given-name><ce:surname>Pae</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Signal Transduct.</sb:maintitle></sb:title><sb:volume-nr>2011</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>792639</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>[49]</ce:label><sb:reference id="rf0245"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Murphy</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Grzybycki</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Glial NO: Normal and pathological roles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuroscientist</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>90</sb:first-page><sb:last-page>99</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0250"><ce:label>[50]</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Zeng</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>P.Y.</ce:given-name><ce:surname>Hwang</ce:surname></sb:author><sb:author><ce:given-name>W.C.</ce:given-name><ce:surname>Yee</ce:surname></sb:author><sb:author><ce:given-name>Y.K.</ce:given-name><ce:surname>Ng</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Wang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Ther.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>314</sb:first-page><sb:last-page>320</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0255"><ce:label>[51]</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Ginn</ce:surname></sb:author><sb:author><ce:given-name>I.E.</ce:given-name><ce:surname>Alexander</ce:surname></sb:author><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Edelstein</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Abedi</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wixon</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene therapy clinical trials worldwide to 2012 - an update</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Gene Med.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>65</sb:first-page><sb:last-page>77</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0260"><ce:label>[52]</ce:label><sb:reference id="rf0260"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Goss</ce:surname></sb:author><sb:author><ce:given-name>W.F.</ce:given-name><ce:surname>Goins</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Glorioso</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Gene therapy applications for the treatment of neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Expert Rev. Neurother.</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>487</sb:first-page><sb:last-page>506</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0265"><ce:label>[53]</ce:label><sb:reference id="rf0265"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.N.</ce:given-name><ce:surname>Campbell</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Meyer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Mechanism of neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuron</sb:maintitle></sb:title><sb:volume-nr>52</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>77</sb:first-page><sb:last-page>92</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0270"><ce:label>[54]</ce:label><sb:reference id="rf0270"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>K.R.</ce:given-name><ce:surname>Penzkover</ce:surname></sb:author><sb:author><ce:given-name>R.G.</ce:given-name><ce:surname>Soderquist</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Spinal interleukin-10 therapy to treat peripheral neuropathic pain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuromodulation</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:issue-nr>6</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>520</sb:first-page><sb:last-page>526</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0275"><ce:label>[55]</ce:label><sb:reference id="rf0275"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.S.</ce:given-name><ce:surname>Miraucourt</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Dallel</ce:surname></sb:author><sb:author><ce:given-name>D.L.</ce:given-name><ce:surname>Voisin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Glycine inhibitory dysfunction turns touch into pain through PKCgamma interneurons</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS One</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:issue-nr>11</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>e1116</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0280"><ce:label>[56]</ce:label><sb:reference id="rf0280"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>R.G.</ce:given-name><ce:surname>Soderquist</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Mahoney</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Long-term control of neuropathic pain in a non-viral gene therapy paradigm</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Gene Ther.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:issue-nr>4</sb:issue-nr><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>470</sb:first-page><sb:last-page>475</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0285"><ce:label>[57]</ce:label><sb:reference id="rf0285"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Bharali</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Klejbor</ce:surname></sb:author><sb:author><ce:given-name>E.K.</ce:given-name><ce:surname>Stachowiak</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Dutta</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Roy</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Kaur</ce:surname></sb:author><sb:author><ce:given-name>E.J.</ce:given-name><ce:surname>Bergey</ce:surname></sb:author><sb:author><ce:given-name>P.N.</ce:given-name><ce:surname>Prasad</ce:surname></sb:author><sb:author><ce:given-name>M.K.</ce:given-name><ce:surname>Stachowiak</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>102</sb:volume-nr></sb:series><sb:issue-nr>32</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>11539</sb:first-page><sb:last-page>11544</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0290"><ce:label>[58]</ce:label><sb:reference id="rf0290"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Roy</ce:surname></sb:author><sb:author><ce:given-name>T.Y.</ce:given-name><ce:surname>Ohulchanskyy</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Bharali</ce:surname></sb:author><sb:author><ce:given-name>H.E.</ce:given-name><ce:surname>Pudavar</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Mistretta</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Kaur</ce:surname></sb:author><sb:author><ce:given-name>P.N.</ce:given-name><ce:surname>Prasad</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>102</sb:volume-nr></sb:series><sb:issue-nr>2</sb:issue-nr><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>279</sb:first-page><sb:last-page>284</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0295"><ce:label>[59]</ce:label><sb:reference id="rf0295"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Ledeboer</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>K.W.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Chavez</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Paclitaxel-induced mechanical allodynia in rats is inhibited by spinal delivery of plasmid DNA encoding interleukin-10</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Proceedings of the 11th World Congress on Pain</sb:maintitle></sb:title><sb:date>2006</sb:date><sb:publisher><sb:name>International Association for the Study of Pain</sb:name><sb:location>Sydney, Australia</sb:location></sb:publisher></sb:edited-book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0300"><ce:label>[60]</ce:label><sb:reference id="rf0300"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.D.</ce:given-name><ce:surname>Milligan</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Sloane</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Langer</ce:surname></sb:author><sb:author><ce:given-name>P.E.</ce:given-name><ce:surname>Cruz</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Chacur</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Spataro</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wieseler-Frank</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Hammack</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Maier</ce:surname></sb:author><sb:author><ce:given-name>T.R.</ce:given-name><ce:surname>Flotte</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Forsayeth</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Leinwand</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Chavez</ce:surname></sb:author><sb:author><ce:given-name>L.R.</ce:given-name><ce:surname>Watkins</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pain</sb:maintitle></sb:title><sb:volume-nr>1</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>9</sb:first-page><sb:last-page>22</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>